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Abstract 
Background: The incidence of malignant melanoma is still rising among fair-
skinned people worldwide, and it is among the three major cancer types in young 
adults in Norway. Progression free survival and overall survival have improved for 
metastatic melanoma, but there is still a need to improve treatment options. Only 
about 50% of the melanomas are BRAF mutated and not all patients are eligible to 
immunotherapy or respond to this kind of treatment. Therefore, further treatment 
options and validated predictive markers needs to be investigated. 
Purpose: This PhD project is based on a clinical Phase II trial that investigated 
efficacy and safety of bevacizumab monotherapy in patients with metastatic 
melanoma. Based on the encouraging results of a disease control rate of 31%, we 
wanted to investigate predictive markers in tissues and blood samples. 
Material and Methods: 35 patients with metastatic melanoma in progression were 
included in this clinical Phase II trial conducted at Haukeland University Hospital. 
Bevacizumab was given in a dosage of 10mg/kg every second week until disease 
progression or unacceptable toxicity. Blood pressure was monitored at every 
treatment cycle. The primary endpoint was objective response (OR) including 
patients with complete response (CR) or partial response (PR) according to RECIST 
guidelines as well as disease control (DC) including patients with stable disease (SD) 
for more than 6 months in addition. Tissues from primary tumors and metastases as 
well as blood samples were collected. BRAF and NRAS mutation status was assessed 
(Paper I). 
In this work, we focused on investigations in serum and plasma samples taken before 
treatment with bevacizumab was started. We performed immunohistochemical 
staining of whole tissue sections from primary melanomas and metastases. Based on 
pre-specified hypotheses, we investigated the angiogenesis-related markers VEGF-A, 
its splicing variant VEGF-A165b, bFGF and HSP27 (Paper II). Microvessel density, 
the number of proliferating vessels and the presence of glomeruloid proliferations 
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(GMPs) were also assessed in tissue samples. In addition, we analyzed serum 
concentrations of VEGF-A, bFGF and HSP27 by ELISA (Paper II).  
Furthermore, we investigated 60 angiogenesis-related proteins in serum samples by a 
multiplex array. Unsupervised hierarchical clustering as well as supervised analysis 
for particular proteins were performed. Candidate proteins that were associated with 
response to treatment were further validated by immunohistochemistry and ELISA 
(Paper III).  
Results: 6/35 patients had objective response (OR) to treatment with bevacizumab 
monotherapy and 5 more patients had stable disease, resulting in a disease control 
(DC) rate of 31%. Responses were observed independently of BRAF and NRAS 
mutation status. Development of early hypertension was associated with a better DC-
rate and may serve as a clinical predictive marker (Paper I).  
Strong expression of HSP27 in metastases was associated with objective response to 
bevacizumab monotherapy. Strong expression of VEGF-A was associated with a 
higher number of proliferating vessels in primary melanomas and with a higher 
number of microvessels in metastases. However, microvessel density, the number of 
proliferating vessels or presence of GMPs in metastases were not associated with 
response to treatment. Serum concentration of VEGF-A, bFGF and HSP27 could not 
predict treatment response (Paper II).  
Unsupervised hierarchical clustering of serum concentrations assessed by the 
multiplex array did not show any specific pattern. Proteins with a defined fold change 
difference between responders and non-responders were further investigated by 
specific analysis. Low serum concentration of Activin A as well as high serum 
concentrations of IL1b, uPAR and VEGF-A were associated with objective response 
to bevacizumab monotherapy. Single protein ELISA was performed for these 
candidate proteins but could not confirm the results from the multiplex array. 
However, strong expression by immunohistochemistry of Activin A, IL1b and uPAR 
in tumor cells from metastases was associated with objective response to 
bevacizumab monotherapy (Paper III). 
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Conclusions: Treatment with bevacizumab monotherapy showed promising efficacy 
in patients with metastatic malignant melanoma in progression. Development of early 
hypertension may be a potential clinical predictor. We identified strong expression of 
HSP27, Activin A, IL1b and uPAR in metastases as possible predictive markers. 
Since our results are based on a single-arm trial with limited sample size, they have to 
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The incidence of cutaneous malignant melanoma (CMM) has been increasing 
worldwide among fair-skinned populations over the last decades1-4. GLOBOCAN 
reported the highest incidence rates in Australia (40.3 per 100.000) and New Zealand 
(30.5 per 100.000), followed by a rate of over 10 per 100.000 in Northern and 
Western Europe and Northern America5. In contrast, incidence rates are 10 to 20-fold 
lower in non-white populations5,6. In general, the number of localized thin melanomas 
is increasing in white populations and especially among younger women7.  
The incidence rate in Norway is among the highest worldwide and has been 
increasing approximately tenfold since the 1950s with a temporary stabilization in the 
1990s8. Incidence rates in men rise above those for women at the age of fifty years8. 
In total, 2.003 new cases of malignant melanoma were reported in the latest update 
from the Norwegian Cancer Registry in 2014; the age standardized incidence rate was 
37.1 for women and 42.2 for men per 100.000 person-years during the period from 
2010 to 20149. CMM is the second most common cancer in young adults (25-49 
years old) in Norway9.  
The relative survival rate was higher in women and in younger patients9. The latest 
survival rate was almost 90% for localized melanoma but only about 18% in 
melanoma patients with distant metastases9. The latest age-standardized mortality rate 
was 7.7 for men and 5.2 for women per 100.000 person-years in Norway9. The 
mortality rate for melanoma is been among the highest in Europa10. Figure 1 
illustrates the incidence, mortality and survival of malignant melanoma in Norway 




Figure 1. Incidence, mortality and survival for malignant melanoma in Norway9 
 
 
Reprinted by permission of the Norwegian Cancer Registry 
 
1.2 Etiology and risk factors 
1.2.1 Phenotypic factors 
The predisposed phenotypes for development of malignant melanoma are described 
by skin type I and II11. People with this skin types are characterized by green eyes, 
fair skin, freckles, blond or red hair and the tendency to get sunburned very easily. A 
big meta-analysis verified significantly increased risk for malignant melanoma for 
these phenotypical features12. Type and amount of melanin pigment produced by 
melanoncytes determine the color of skin and hair13. The melanocortin-1 receptor 
(MCR1) is expressed in melanocytes and melanoma cells and is one of the best 
known regulators of pigmentation13,14. Variations in the MCR1 gene are associated 
with phenotypic characteristics of skin type I and II15,16. 
Furthermore, increasing numbers of melanocytic nevi and dysplastic nevi are 
independent risk factors for cutaneous melanoma7,17,18. The relative risk for 
melanoma was more than six times higher in patients with more than five atypical 
 21 
nevi in a meta-analysis from case-controlled studies19. Architectural disorder and 
cytologic atypia are major criteria in definition of dysplastic nevi20,21. Clinical 
characteristics of dysplastic nevi defined by Tucker et al. in a large case-control 
study18 were: size >= 5 mm, presence of a flat component as well as variable 
pigmentation, irregular outline and fuzzy borders.  
B-K mole syndrome22, familial atypical multiple-mole melanoma (FAMMM) 
syndrome23 and dysplastic nevus syndrome24 describe nevus phenotypes in 
melanoma-prone families. Clark, Lynch and Elder use different criteria in their 
reports and still today, there is no consensus about required diagnostic features25. The 
NIH consensus conference requires melanoma in first or second-degree relatives, > 
50 clinical atypical nevi and distinct histological features for diagnosis of DNS. 
Thereby, this consensus is the only one that includes histology in diagnosis of 
FAMMM syndrome25.   
Another known risk factor are large congenital melanocytic nevi, defined by a 
diameter greater than 20 cm (Hale, EK BR J Dermatology 2005). Those nevi can 
develop into early onset melanomas in ca. 2-3%, a mean age of 12.6 years is reported 
in a recent review at diagnosis26,27. 
1.2.2 UV radiation 
UV radiation is a well-known risk factor for cutaneous melanoma. UVA radiation has 
longer wavelength (320 - 400nm), represents the major part of solar radiation and can 
penetrate deeper in the tissue than UVB radiation with shorter wavelength (280-320 
nm). Both UVA and UVB radiation can induce cyclobutane pyrimidine dimers that 
are mutagenic. UVA radiation induces in addition oxidative DNA damage in 
melanocytes28-30. The most common UV- induced DNA damages are C>T and 
CC>TT transitions, also called fingerprint mutations. This kind of mutations accounts 
for the majority of somatic mutations in melanoma31. UV radiation is also the reason 
for that melanoma has the highest rate of somatic mutations among all cancer types32. 
Furthermore, CDKN2A and TP53 mutated melanomas showed an increased rate of 
UV fingerprint mutations33. 
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Meta-analyses and case-control studies showed that the history of sunburn has 
significant impact on melanoma risk34-36 and this association was seen during all 
periods of lifetime (childhood/adolescence and adulthood)36-38. However, several 
migration studies investigated the association between age of migration to lower 
latitude or more sunny destinations and risk of melanoma. Migration during 
childhood was correlated to a higher melanoma risk compared to migration at later 
ages39. These observations were used to postulate that increased sun exposure during 
childhood is associated to higher risk for melanoma. 
Another risk factor is intermittent sun exposure, probably because of DNA damage 
due to relatively high dose UV radiation on insufficient protected skin34,36,37. 
Possibly, people living in higher latitudes experience more intermittent sunburn while 
traveling to more sunny regions. However, the pattern of sun exposure must be 
looked at in more detail, since chronic, often occupational sun exposure was inversely 
associated to melanoma34,37 and repeated weekend exposure was protective except for 
people with red hair35. Conversely, others found a positive association between 
increased occupational sun exposure and melanoma on the head and neck36,40.  
The use of sunbeds is also an accepted risk factor for melanoma41 and this risk is 
especially high for younger people as shown in several studies42-45. The European 
Code against cancer recommends avoiding sunbeds46 also the FDA restricts the usage 
of indoor tanning devices to persons above the age of 18 years47. In Norway, sunbed 
use is not allowed for people younger than 18 years9.  
There is ongoing controversial discussion about the role of Vitamin D in cutaneous 
melanoma. Several epidemiologic studies and cohort studies suggest that higher 
vitamin D levels may be associated with lower incidence of cancer and other diseases 
and better outcome48. Synthesis of vitamin D in keratinocytes is catalyzed by UV 
radiation and in vitro studies showed different anti-tumor effects48,49. A recently 
published meta-analysis did not find any significant association between vitamin D 
serum levels or dietary intake and the risk for melanoma; however, an inverse 
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correlation between Breslow thickness and vitamin D serum levels was described in 
some of the included studies49. 
Acral lentiginous melanoma is the most common subtype among blacks50. However, 
the highest incidence of this subtype is reported in Hispanics50. It is suggested, that 
more pigmented skin protects better against UV radiation but there is ongoing 
discussion about the mechanisms51.  
1.2.3 Hereditary risk factors 
About 5 -10% of melanomas are caused by germline mutations and in approximately 
20 - 40% of families with hereditary predisposition the mutation can be identified52,53. 
Hereditary melanoma is often characterized by early onset, occurrence of multiple 
primary melanomas and the presence of dysplastic nevi52. The tumor suppressor gene 
cyclin-dependent kinase inhibitor 2A (CDKN2A) encodes two distinct proteins by 
alternatively splicing54. About 20-40% of melanomas with hereditary predisposition 
are caused by CDKN2A mutations and a geographically variability in penetrance is 
described52,53,55. The CDKN2A mutations are found in a high percentage of patients 
with FAMMM-syndrome; furthermore, these mutations comprise also increased risk 
for pancreatic cancer53. Melanoma risk is lower for CDKN2A carriers in the general 
population without familial melanoma history55,56.  
Other high penetrance genes are Cyclin-dependent-kinase-4 (CDK4), BRCA1 
associated protein-1 (BAP1), Protection of telomeres 1 (POT1), adrenocortical 
dysplasia protein homolog (ACD)/telomeric repeat binding factor 2 interacting 
protein (TERF2IP) and Telomerase RT (TERT). CDK4 is probably the best described 
melanoma predisposition gene along with CDKN2A. Compared to mutations in 
CDKN2A, the point mutation in CDK4 is less frequent but its penetrance is quite high 
(74%) at the age of 50 years57. In addition, a high frequency of BRAF mutations is 
described in melanomas with CDK4 mutations58. Increased risk of developing other 
cancer types in addition, has been reported in melanoma patients with BAP1 or POT1 
mutations55.  
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Germline mutations with medium penetrance are less likely oncogenic driver genes 
on their own but cross-signaling between several of these alleles may increase 
melanoma risk55. Melanocortin 1 receptor gene (MC1R) mutation is associated with a 
two-fold increase52. The presence of more than one MC1R variant doubled the 
melanoma risk in CDKN2A mutation carriers, and carriers of multiple MC1R variants 
had a four time higher melanoma risk59. Other medium penetrance genes are the 
microphthalmnia-associated transcription factor (MITF) which is an important 
regulator of pigment cells, and solute carrier family 45, member 2 (SLC45A2) 
variants that are associated with more pigmented skin55. Furthermore, loci of low 
penetrations genes that are associated with increased melanoma susceptibility, were 
identified in Genome-wide association studies (GWAS)60,61, others were reported in a 
recent review55. Finally, various hereditary syndromes which include also raised 
occurrence of melanoma are known. Xeroderma pigmentosum is an autosomal 
recessive syndrome in which DNA damage caused by UV radiation cannot be 
repaired properly. The Li-Fraumeni Syndrome, familial retinoblastoma syndrome, 




1.3 Clinical aspects in primary melanomas 
Early diagnosis of primary melanomas is essential since thin tumors have excellent 
prognosis. Friedman et al. defined characteristic clinical features, the so-called 
ABCD- criteria, already in 198562. “Evolving” was added as fifth feature about 20 
years later, and describes any change due to size, shape, color surface features or 
symptoms over time63. The ABCDE criteria are shown in Table 1. 
Table 1. The ABCDE criteria 
A Asymmetry 
B Irregular Borders 
C Multiple colors 
D Diameter > 6 mm 
E 
Evolving (with respect to size, shape, shades of 
color, surface features or symptoms) 
Modified by N. R. Abbasi, 200463 
These characteristics are useful tools to distinguish melanomas from benign nevi 
when clinical or dermatoscopic examination of pigmented lesions is performed. In 
addition, the ABCDE-criteria are used in public education campaigns. A recent 
review confirms high sensitivity and specificity of the ABCDE-criteria among 
dermatologists and improved utilization among general practitioners after specific 
training. However, it is more doubtful how useful the criteria are for laypersons64. 
The “ugly duckling” sign describes a nevus that does not share the common features 
of all other nevi in an individual patient and therefore attracts special attention during 
examination of the integument65. These lesions are highly suspicious for melanoma 
and should be further investigated. The inter-observer agreement/sensitivity for 
detection of “ugly duckling” nevi was high66. Other alarming features for melanoma 
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suspicion are bleeding, itching or pain of nevi as well as de-novo appearance of 
quickly growing pigmented lesions.  
1.4 Development, classification and staging 
1.4.1 Developmental aspects 
Melanocytes are melanin containing dendritic cells that derive from neural crest cells 
and migrate to the epidermis of the trunk along the dorsolateral pathway during 
embryogenesis67,68. Skin melanocytes which settle predominantly in the dorsal and 
lateral body walls as well as the limbs derive from Schwann cell precursors that 
follow the dorso-ventral pathway67.  
1.4.2 Tumor pathogenesis 
The Clark model describes how melanocytes develop to benign and later on 
dysplastic nevi resulting in malignant melanoma. Transmigration of melanoma cells 
from the epidermis into the papillary and reticular dermis is typical in the vertical 
growth phase (VGP). Further uncontrolled proliferation of melanocytes in the 
epidermis and loss of contact to keratinocytes due to a loss of E-cadherin 
characterizes the radial growth phase68,69. This pathogenesis is often seen in 
melanomas developing after non-cumulative sun-induced damage70.  However, 
melanomas often develop from normal skin as a result of UV radiation induced DNA 
damage that is not adequately repaired28,70. Whereas severely damaged keratinocytes 
undergo apoptosis, substantially damaged melanocytes do survive and divide before 
mutations are repaired properly28. Also, other oncogenic events like loss-of-function 
alterations of tumor suppressor genes or epigenetic alterations play a role in 
melananomagenesis70. Furthermore, solar stimulated UV radiation in general 
suppresses immune response, and UVA as well as UVB radiation contribute by 
various specific mechanisms71.  
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1.4.3 Histological classification 
Clark et al. described the histology of superficial spreading melanoma (SSM), 
nodular melanoma (NM) and the lentigo maligna melanoma (LMM) for the first time 
in 196972. During the Cancer Conference in Sydney in 1972, a classification and 
nomenclature was standardized by pathologists73; the current classification of 
melanoma includes acral lentiginous melanoma (ALM) as the fourth major histologic 
subtype. SSM is the most common subtype in Caucasians, diagnosed in 65-70% of all 
primary melanomas and mostly seen on sun exposed sides like the trunk and the 
lower limbs. NM accounts for about 15-20%, followed by LMM (13%) which is 
often diagnosed on long-term sun exposure skin in elderly people74,75. ALM is the 
rarest type (2-3%) and predominantly found on the palms, soles and nail beds; the 
proportion of this subtype is much higher in blacks (36%) and non-Hispanic 
Whites75,76. 
1.4.4 Molecular classification 
During the last two decades, several somatic mutations associated to distinct subtypes 
of melanoma has been discovered. The mitogen-activated protein kinase (MAPK) 
pathway and the PTEN/AKT pathway play a key role in cell proliferation in 
melanocytic lesions.  
BRAF mutations are seen in 50- 60% of melanomas, and the V600E mutation in exon 
15 is the most commonly observed alteration77-79. BRAF mutations are frequently 
found in SSM and NM in younger patients on intermittent sun-exposed skin, and are 
often associated with the presence of acquired melanocytic nevi and metastasize 
preferably to regional lymph nodes70,80. The BRAFV600E mutation is the most common 
driver mutation81. It is found in a high percentage of melanocytic nevi, suggesting 
that this mutation occurs early in melanomagenesis15,70,82.  
NRAS mutations account for about 15% of all somatic mutations in melanomas on 
non-chronic sun damaged skin (non-CSD), CSD, acral and mucosal melanomas70,78. 
Mutations in this gene are most common in codon 6178,83. Presently, there are 
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controversial observations regarding association between NRAS mutation and sun 
exposure, body site of primary melanoma, histopathological subtype or other 
histologic features80. NRAS mutations have been associated with significantly greater 
Breslow depth compared to wild type or BRAF mutated melanomas78. Compared to 
BRAF mutations, NRAS mutations are non-significantly more frequent in elderly 
patients79.  
In 2015, mutant NF1 and Triple wild type were suggested as two additional subtypes 
in the genomic classification of cutaneous melanoma84. NF1 mutations are loss of 
function mutations that result in alternatively activation of the MAPK pathway. The 
Triple wild type encloses a heterogeneous subgroup of melanomas that lacks BRAF, 
NRAS or NF1 mutations84. KIT, GNAQ or PTEN mutations are included in this group 
among others84. KIT mutations are seen in approximately 15% of acral, mucosal and 
CSD-melanomas. They arise often in elderly people (>60 years) and are not 
correlated to the presence of acquired melanocytic nevi70,80. GNAQ or GNA11 
mutations are exclusively observed in uveal and blue-nevus like melanomas70. PTEN 
mutations are described in non-CSD, acral and mucosal melanomas70. PTEN and 
BRAF mutations are often present concurrently, resulting in co-activation of the 
MAPK and the PI3K pathway15. 
1.4.5 pTNM classification of melanoma 
The pathologic tumor-node-metastases (pTNM) classification in its 7th edition 
summarizes prognostic variables that should be reported when primary melanomas 
are histologically assessed85,86.  
Primary tumors (T) are classified by tumor thickness and the absence or presence of 
ulceration. In addition, the mitotic rate (mitoses/mm2) was implemented to 
distinguish between stage T1a and T1b, see Table 2. The level of invasion as defined 
by Clark72 is the weakest prognostic factor; it is therefore only relevant to determine 
stage T1b when the mitotic rate cannot be investigated properly.  
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Tumor thickness by Breslow is measured from the top of the granular layer of the 
epidermis to the deepest infiltrating tumor cells87. 
Tumor ulceration is defined as “the interruption of the surface epithelium involved by 
the tumor”88. 
The mitotic rate is the number of mitoses assessed in an area corresponding to 1 mm2 
within a hot-spot area in the dermis86,89,90. 
 
Table 2. T-classification in cutaneous melanoma 
T classification Thickness (mm) Ulceration/mitosis 
Tis not applicable not applicable 
T1 ≤ 1.0 a: +/- ulceration and mitosis < 1/mm2  
b: + ulceration or mitosis ≥ 1/mm2 
T2 1.01 - 2.0 a: +/- ulceration 
b: + ulceration 
T3 2.01 - 4.0 a: +/- ulceration 
b: + ulceration 
T4 > 4.0 a: +/- ulceration 
b: + ulceration 
Modified from Balch et al.86 
 
The N-stage is defined by the number of affected regional lymph nodes and include 
in transit metastases and microscopic satellites (Table 3). Metastases that are only 
documented pathologically are “microscopic” nodal metastases and are in contrast to 
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macroscopic metastases that are diagnosed by clinical or radiologic examination. 
There is no threshold for a minimum size of microscopic metastases86. The site of 
distant metastases and serum levels of lactate dehydrogenase (LDH) define M-
categories (Table 4)86. 
 
Table 3. N-classification in cutaneous melanoma 
N classification Number of metastatic nodes Nodal metastatic burden 
N0 0 not applicable 
N1 1 a: micrometastases* 
b: macrometastases^ 
N2 2 - 3 a: micrometastases* 
b: macrometastases^ 
N3 4+ or matted nodes or in 
transit met/satellites with 
metastatic nodes 
c: in transit metastases or 
satellites without metastastic 
nodes 
* diagnosed after sentinel node biopsy; ^ defined as clinically detectable nodal 
metastases pathologically confirmed. 
Modified from Balch et al.86 
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Table 4. M-classification in cutaneous melanoma 
M classification Site Serum LDH 
0 no distant met1 not applicable 
M1a distant skin, subcutaneous or nodal met normal 
M1b lung metastases normal 
M1c all other visceral met 
any distant met 
normal 
elevated 
1 met: metastases. Modified from Balch et al.86 
 
1.4.6 Sentinel node biopsy 
Sentinel node biopsy (SLNB) in melanoma was described for the first time in 199291. 
Briefly, a radiotracer is injected intradermally around the primary melanoma the day 
before surgery; additional blue dye injection in the beginning of the surgical 
procedure is optional. The node with highest radioactivity is identified with a gamma 
probe and removed92.  
Common guidelines from The American Society of Clinical Oncology (ASCO) and 
Society of Surgical Oncology (SSO) published in 2012, recommend SLNB for 
patients with intermediate-thickness melanomas (Breslow thickness 1-4 mm) 
regardless of the anatomic site, and the performance of complete lymph node 
dissection (CLND) in case of positive SLNB93; the AJCC staging system emphasizes 
SLNB also for patients with stage T1b86. The Norwegian guidelines are in accordance 
with the international recommendations94.   
The recently published 10-year follow-up data from a phase 3 trial that randomized 
patients with intermediate-thickness melanomas for SLNB versus observation did not 
show significant difference in melanoma specific survival rates when node positive 
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and node negative patients were analyzed together95. Within the group who 
underwent SLNB however, positive sentinel-node status was the strongest predictor 
of disease recurrence and melanoma specific death in patients with intermediate-
thickness or thick melanomas95. About 20% of patients with intermediate-thickness 
melanomas had positive node biopsies95. Thus, the number of unnecessary SLNBs 
should be reduced. There is ongoing research to find additional clinicopathological 
variables that can identify the patients who will benefit from SLNB. Breslow 
thickness, lymphovascular invasion and localization of the primary tumor on the 
trunk were recently associated with patients at risk for positive sentinel nodes96. 
Meves et al. suggests a model that combines clinicopathologic variables like age, 
Breslow thickness and ulceration with a gene signature linked to cell-adhesion genes 
to predict the likelihood of sentinel node metastases97.  
The ongoing EORTC Minitub trial and the MSLT-2 trial are investigating the role of 
CLND vs observation in patients with positive SLNB98,99.   
In conclusion, SLNB is an established staging modality in patients with intermediate-
thickness melanomas but there is an ongoing discussion regarding patients with thin 
melanomas. Additionally, markers for better prediction of sentinel node positivity are 
needed. Also the benefit of CLND in node positive patients remains to be 
investigated further.  
1.5 Tumor biology - important hallmarks of cancer in 
melanoma 
The hallmarks of cancer define important features of tumors that enable their growth 
and ability to metastasize and describe their interaction with the microenvironment100. 
These characteristics include sustained proliferation, resistance to cell death, 
activation of invasion and metastasis, inducing angiogenesis and evasion from 
immune response100. Several of these traits also play an important role in melanoma 
development and progression. Furthermore, melanomas have a very high number of 
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somatic mutations that contribute to enhanced proliferation and tumor growth due to 
activation of oncogenes and inhibition of tumor suppressor genes32,70. 
1.5.1 Cell cycle regulation 
The mammalian cell cycle consists of four phases, the first gap phase (G1), the 
synthetic phase (S), the second gap phase (G2) and mitosis (M). In addition, there is a 
non-proliferating G0 state. The G1-phase starts after the previous cell division is 
completed and the decision about entering a new growth phase or becoming 
quiescence is made. This decision depends on extracellular growth-regulating signals 
and cannot be diminished after passing the restriction point (R-point) in the late G1-
phase. At this point it is determined if the cell stays in G1, switches to G0 or moves 
on to late G1 and S-phase. Growing cells replicate DNA during S-phase, continue 
into G2-phase and finally start mitosis. The M-phase includes prophase, metaphase, 
anaphase and telophase. DNA replication and division of chromatids are extremely 
critical steps in cell division101. Checkpoints in G1, at G1/S transition, at G2/M 
transition and at the metaphase/anaphase transition ensure that every single step in 
each phase is performed exactly before moving on101,102. Cyclin-depending kinases 
(CDKs) together with their corresponding regulatory subunits, the cyclin protein, are 
important players in cell cycle regulation. These CDKs can be inhibited by various 
CDK inhibitors. p16, p15, p18 and p19 specifically inhibit CDK4/6; p21, p27 and 
p57 inhibit the four other complexes shown in Figure 2. 
The G1/S checkpoint seems to be crucial in melanomagenesis and progression 
whereas alterations in the retinoblastoma protein (Rb) pathway are relatively 
common. Mutations in the p53 pathway are less frequent 102.  




Figure 2. Pairing of cyclins with cyclin-dependent kinases during the cell cycle 
 
(c) 2007 from “The Biology of Cancer” by Weinberg. Reproduced by permission of Garland 
Science/Taylor & Francis Group LLC 
 
pRB pathway 
pRb, p16, Cyclin D1 and p27 are important elements in the pRB pathway. pRB is the 
gatekeeper at the R-point in late G1-phase. In its unphosphorylated state, it is bound 
to E2F transcription factors and acts as a growth suppressor. When phosphorylated by 
D-CDK4/6 during G1, it releases the transcription factors and becomes functionally 
inactive after hyperphosphorylation by E-CDK2 in late G1. As a consequence, it 
loses its inhibitory function and cells can pass through into S-phase101,102.  Inherited 
mutations in Rb predispose to melanoma and other tumors102.  
p16 is coded by the CDKN2A gene and its binding to CDK4/6 inhibits the formation 
of the active D-CDK4/6 complex; consecutively, Rb will not be phosphorylated and 
the cell remains in G1 phase102.  
p27 regulates activation of D-CDK4 and E-CDK2102. 
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Cycline D1 is coded by the CCND1 gene and its binding to CDK4/6 activates the 
kinase. CCND1 amplification impact on melanoma progression is controversially102. 
p53 pathway 
p53 is encoded by the TP53 gene and is entitled “the guardian of the genome”. p53 
becomes activated in case of DNA damage, and either arrests the cell in G1 phase or 
induces apoptosis. When DNA damage occurs, p14 transfers the signal to MDM2 
which in turn activates release of p53 from the MDM2/p53 complex; finally, p53 is 
activated by phosphorylation102. Various frequencies of TP53 mutations are reported 
in melanoma and there is evidence for UV radiation related genesis of gene 
alterations102. In contrast to other cancers, p53 protein expression in melanoma can be 
increased independently from TP53 mutation status, indicating that stress related to 
DNA damage or hypoxia might induce upregulation102.  
p21 is encoded by the RAS gene and is the main mediator of p53 induced growth 
suppression. Upregulation of p21 results in an increased number of p21-D1-CDK4 
complexes which inhibits action of D1-CDK4, and thereby also phosphorylation of 
Rb102. Alterations in the p21 gene are rare in melanoma and other tumors. Increased 
expression of p21 in melanoma is shown in the majority of studies with decreasing 
frequency in metastatic lesions102. 
In case of severe DNA damage, p53 triggers apoptosis, mainly through the intrinsic 
apoptotic program by upregulation of pro-apoptotic factors104. p53 activates 
expression of apoptotic protease activating factor 1 (APAF-1) and expression of 
members of the Bcl-2 family. One of these proteins induces cytochrome C release 
from the mitochondria which in turn activates caspase 9. Cytochrome C, caspase 9 
and APAF-1 form the apoptosome. Caspase 9 is activated in this complex and 
promotes consecutively activation of other down-stream caspases resulting in 
apoptosis of the cell105. Furthermore, p53 can initiate apoptosis via the extrinsic 
pathway by inducing expression of transmembrane death receptors like FasR or 
TNFR1106.  
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Mitogen-activated protein kinase (MAPK) pathway 
Activation of receptor tyrosine kinases (RTK) on the cell surface by growth factors 
initiates the MAPK pathway. Interaction of RTK with RAS, a membrane bound 
GTPase, starts the intracellular signaling cascade. RAS activates RAF that 
phosphorylates MEK which in turn activates ERK. Phosphorylated ERK affects 
various downstream targets resulting in increased proliferation, survival, invasiveness 
and angiogenesis107. BRAF and NRAS mutations are mutually exclusive.  
Phosphatidylinositol 3-kinase (PI3K) pathway  
c-KIT is another RTK that can activate the MAPK or PI3K pathway. RAS can 
alternatively activate PI3K which phosphorylates AKT via PIP3. Activated AKT 
promotes cell survival, proliferation, angiogenesis and other processes15,108. The 
tumor suppressor PTEN antagonizes the activity of PI3K by dephosphorylating PIP3.  
1.5.2 Angiogenesis 
Angiogenesis is the formation of new vessels from preexisting vessels. Folkman 
observed that tumor growth beyond a diameter of 1-2 mm2 depends on 
neovascularization and entitled the responsible growth factor “tumor-angiogensis 
factor (TAF)”109,110; his group suggested that the crosstalk between TAF and 
endothelial cells (ECs) promotes angiogenesis111. The process of angiogenesis and its 
role in tumor growth and metastasis is described in detail by Bielenberg and Zetter112. 
Furthermore, it was observed that avascular tumors persisted in a stable “dormant” 
status for many years but grew exponentially when they became vascularized113,114. 
The balance between pro and anti-angiogenic factors determines if tumor dormancy 
or neovascularization and growth dominate tumor biology115. The change in 
vascularization status was called the “angiogenic switch”. Figure 3 gives an 
overview of important factors in this balance.  
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Figure 3. Balance between pro-and anti-angiogenic factors 
Based on “Angiogenesis: regulators and clinical applications”116 
 
Algire was the first to observe vascularization in melanoma transplanted to the mouse 
in a transparent chamber in 1943117. High vascularization in primary melanomas is 
correlated with worse prognosis and is an independent factor in multivariate analysis 
in line or even superior to tumor thickness118-120. Furthermore, it has been shown that 
several growth factors, integrins and matrix metalloproteinases play an important role 
in melanoma angiogenesis121. 
Vascular permeability factor (VPF) was purified in 1983122 and later on renamed as 
vascular endothelial growth factor A (VEGF-A)123. The VEGF-A family consists of 
five members, VEGF-A to VEGF-D and placenta growth factor (PlGF), and belongs 
to the platelet-derived growth factor supergene family124. VEGF-A plays a key role in 
physiological and pathological angiogenesis, activates proliferation and migration of 
endothelial cells, induces vascular leakage and vasodilatation125,126. Alternative 
splicing of the VEGF-A gene results in several pro-angiogenic isoforms (VEGF121, 
VEGF145, VEGF148, VEGF165, VEGF183, VEGF189, VEGF206) as well as anti-
angiogenic VEGF-Axxxb isoforms that have a different C-terminus127. VEGF165 is the 
most common isoform and exists heparin-bound or secreted125. Hypoxia, several 
cytokines and growth factors as well as oncogenes or tumor suppressor genes 
upregulate VEGF expression128. VEGF binds to the tyrosine kinase receptors 
VEGFR-1 and 2 on ECs and tumor cells; its binding to VEGFR-2 is an important step 
in angiogenesis and activates further downstream signaling via PIK3 and 
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phospholipase Cy pathways129. Conversely, binding of VEGFxxxb to VEGFR-2 seems 
to inhibit the key functions of VEGF-A127. VEGF-A expression is reported in primary 
melanomas as well as metastases119. VEGFxxxb expression was observed in normal 
dermis and other normal tissues, however, it is downregulated or absent in tumor 
tissue127; absence of VEGFxxxb characterized primary melanomas that did metastasize 
compared to non-metastasizing cases130.  
Basic fibroblast growth factor (bFGF) was described for the first time in 1984123,131. 
bFGF is involved in various oncogenic mechanisms, here we focus on its role in 
angiogenesis. bFGF binds to tyrosine kinase FGFRs on the surface of endothelial 
cells and activates their proliferation and migration as well as extracellular matrix 
(ECM) degradation132. Inhibition of bFGF and FGFR-1 mediated signaling abolished 
angiogenesis in human melanoma xenograft tumors133. Furthermore, high 
microvessel density in primary melanomas is associated with expression of bFGF134. 
There is also evidence for a synergistic effect of FGF and VEGF signaling in 
angiogenesis135. 
Recently, the pro-angiogenic role of Heat Shock protein 27 (HSP27) was indicated in 
cell-line studies, xenografts and patient samples136. HSP27 is a family member of 
small heat shock proteins that maintain cell survival under stressful conditions137. 
Various physical, biological or chemical stress signals can increase intracellular 
HSP27 concentration and influence its oligomerization status. HSP27 prevents 
aggregation of misfolded proteins, inhibits apoptosis and interacts with different parts 
of the cytoskeleton137,138. Downregulation of HSP27 in an angiogenic breast cancer 
cell line resulted in decreased secretion of VEGF-A and bFGF, and a non-angiogenic 
phenotype in vivo136. Furthermore, strong expression of HSP27 is reported as a poor 
prognostic factor in various solid tumors136,139,140 and is associated with resistance to 
chemotherapy141,142. 
The urokinase plasmin activator receptor (uPAR) plays a role in proliferation, 
extracellular matrix degeneration, cell motility and invasion143. It is anchored to GPI 
in the cell membrane and lacks a transmembrane domain so that it depends on 
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interaction with other proteins to transfer signals143. VEGF-A induced re-localization 
of uPAR to the leading edge of endothelial cells contributes to angiogenesis144. uPAR 
is not detectable in benign nevi and early stage melanoma, but increased expression is 
reported in more advanced primary lesions and metastases145.  
Interleukin 1b (IL1b) is a pro-inflammatory cytokine produced by tumor cells and 
other cells in the microenvironment. It contributes to angiogenesis by interaction with 
VEGF-A, endothelial cells and myeloid cells146. Examples for this interaction are the 
regulation of expression of VEGF-A and its receptors on ECs by IL1b and synergistic 
effects of IL1b with VEGF-A by increasing gene-expression of growth factors and 
cytokines on ECs146. 
Activin A belongs to the transforming growth factor-b superfamily and its role in 
angiogenesis is more controversial and may depend on tumor type and the 
microenvironment. Activin A stimulates expression of VEGF-A and bFGF in 
vitro147,148 and corneal neovascularization was observed in vivo149. On the other hand, 
Activin A suppressed endothelial cell growth and decreased angiogenesis in a gastric 
cancer model150. 
1.5.3 Invasion and metastasis 
The ability of cancer cells to invade the surrounding tissue and metastasize to distant 
sites in the body is another key feature. Adequate expression of cell adhesion 
molecules maintains a stable state in the basal layer of tissues and controls the 
interaction with the ECM100. One of the best known adhesion molecules in epithelial 
cells is E-cadherin. Loss of E-cadherin and upregulation of N-cadherin characterizes 
many carcinomas100. Various transcriptional repressors of the E-cadherin gene have 
been described, e.g. Snail, Slug, SIP1and E2a151 as well as Twist152. The acquirement 
of more mesenchymal like attributes together with the downregulation of epithelial 
traits during an epithelial mesenchymal transition (EMT) and the reversion of this 
process, mesenchymal-epithelial transition (MET), are key processes during 
metastasizing151. EMT-like processes have also been described in melanoma153. 
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The “seed and soil” theory proposed by Stephen Paget in 1889 is widely accepted. 
Progenitor cells, metastatic cells or cancer steam cells can be “seeds” evolved from 
the primary tumor that may establish metastasis in proper niches or organ 
microenvironments (“soils”)154. Metastasizing includes local invasion into blood 
vessels or lymphatic vessels, transportation of multi-cell aggregates to distant sites, 
arrest in the capillary bed and subsequent extravasation into organ parenchyma and 
finally, establishment in the new microenvironment and further proliferation154. This 
process can be interrupted by the antitumor host response and is therefore completed 
only in a very limited number154. Nowell155 suggested that acquired genetic variability 
during tumor progression together with selection pressure results in more aggressive 
tumor cells. The concept of clonal origin of metastases has been verified by others 
and may explain heterogeneity in response to chemotherapy and course of disease154. 
Melanomas metastasize mainly through the lymphatic system but also via 
haematogenic dissemination to more distant sites like lungs, liver and brain156. 
Various EMT related transcription factors play a role in phenotypic heterogeneity and 
plasticity of melanomas157. Since melanomas are of intermediate mesenchymal 
nature, expression of EMT transcription factors alters depending on the phenotype 158 
as also shown in various in vitro and in vivo models153,159. Expression of E-cadherin 
in normal melanocytes is essential for their contact with keratinocytes in the 
epidermis, however, its loss is characteristic for more invasive late stage 
melanomas153.  
The role of cancer stem cells (CSC) in the pathogenesis of melanoma metastasis is 
still under investigation; however, disease progression, ability of metastasizing and 
poorer prognosis seem to be associated with the presence of CSCs160. CSCs in 
melanoma are also named malignant melanoma initiating cells (MMICs). CSCs are 
characterized by the following traits: the ability to initiate tumor growth, the capacity 
to self-renew and the ability to differentiate into tumor cells160. Two major models 
include CSCs in their explanation of tumor growth and progression161. In the 
hierarchical model, the phenotype of CSCs is stable and self-renewable but cells 
arising from these CSCs lose the ability of self-renew. In contrast, there is the 
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stochastic model in which signals from the microenvironment determine the fate of 
the cancer cells and cells can switch between being a non-stem cell and being a 
CSC161. ABCB5 and CD271 are established markers for MMICs in melanoma160, 
others are still under investigation. Increased expression of CD271 promotes immune 
evasion and expression of ABCB5 is characteristic in chemo-resistant cells. 
Furthermore, MMICs may promote invasion and metastasis due to interaction with 
EMT and MET and further mechanisms are under investigation160. Other melanoma 
stem cell markers are CD20, CD133 and ABCG2161. 
1.5.4 Immune system  
There are three phases of interaction between tumor cells and the immune system 
from the onset of the first tumor cells until the existence of a tumor in progression162. 
First, the innate and adaptive immune system recognizes and eliminates tumor cells. 
During the following equilibrium between remaining tumor cells and the immune 
system, the tumor can stay in dormancy over many years. However, the genetically 
instable tumor cells and the surrounding host immune system continue interaction 
with each other. This process is defined “immune editing”. Finally, the tumor can 
escape from the immune system and proliferates uncontrolled162. Escape mechanisms 
include secretion of cytokines that inhibit or mediate immune response, induction of 
an immune suppressive environment and alteration of important antigens and 
molecules on the surface of the tumor cells themselves162-164. Interference of dentritic 
cell maturation, inappropriate presentation of tumor antigens, deficiency of 
costimulatory molecules involved in T-cell activation or recruitment of immune-
suppressive myeloid-derived suppressor cells (MDSCs) are other approaches to evade 
the host immune system163,164.  
Melanoma is a highly immunogenic tumor and many of the mentioned mechanisms 
play an important role in its progression as well in successful treatment. Vascular 
endothelial growth factor (VEGF) can be secreted by cancer cells and cancer 
associated fibroblasts165. VEGF recruits MDSC and macrophages to the tumor, 
inhibits maturation of dentritic cells and prevents T-lymphocyte invasion125,166,167. 
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High pretreatment levels of VEGF were associated with decreased OS in melanoma 
patients treated with ipilimumab168. Other mechanisms of melanoma cells that are 
associated with immune escape are expression of FasL169 and inadequate expression 
of HLA class I molecules170. 
1.6 Prognostic and predictive factors in melanoma 
A prognostic biomarker defines the risk for the likely outcome of disease at time of 
diagnosis independently of further treatment171,172. Conversely, a predictive 
biomarker identifies the likelihood for response to a particular therapy171. 
1.6.1 Prognostic markers 
Histopathological markers   
The current AJCC staging system provides important prognostic information with 
impact on tumor staging. The database contains prospective data on 30,946 patients 
with stage I, II and III and 7,972 patients with stage IV melanoma from 17 major 
medical centers86,173.  
Tumor thickness as defined by Breslow87 is still one of the most important factors to 
determine T-category and is the strongest predictor for survival in multifactorial 
analysis86. 10-year survival was 96% for patients with 0.01-0.05 mm thick 
melanomas and 42% for patients with melanomas thicker than 6.00 mm. 
Mitotic rate was the second most powerful predictor of survival in a multifactorial 
analysis and was therefore introduced to the AJCC staging system in 200986. A 
threshold of at least 1 mitosis per mm2 showed greatest impact on survival. The 
presence of mitosis is especially important to distinguish stage T1a and T1b. Another 
marker for mitosis is phosphohistone H3 (PHH3) that was an independent prognostic 
factor for OS when investigated in a series of nodular melanomas. Its prognostic 
value was even superior to the assessment of mitotic rate and this marker should be 
further validated in greater series174.  
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Ulceration of the primary melanoma was another important prognostic factor. The 
survival rates for patients with an ulcerated melanoma are quite similar to those for 
patients with a non-ulcerated melanoma in the next higher T-category86. Originally, 
ulceration was defined as the deficiency of intact epithelium. Recent research 
suggests a particular biologic entity for ulcerated melanomas characterized by 
epidermal defect, distinct elements in host response and affection of the surrounding 
epidermis. Furthermore, the presence of ulceration was identified as an independent 
beneficial predictive factor in several studies investigating adjuvant treatment with 
interferon175. 
Tumor thickness, mitotic rate and ulceration predict 10-year survival in T1 tumors. 
The level of invasion which was part of the staging system for many decades is the 
weakest prognostic factor in multivariate analysis in stage I and II tumors and 
therefore only relevant to categorize patients to T1b if the mitotic rate cannot be 
determined86.  
Melanoma growth pattern (vertical versus horizontal tumor growth) is not an 
independent prognostic factor even though melanomas other than SSM and NM may 
have a fairly different prognosis due to various growth patterns.  
Vascular invasion describes the presence of tumor cells within the lumen of vessels 
and was described as independent prognostic marker in primary melanomas176-178 
whereas others did not find any independent prognostic impact179,180. 
Microvessel density (MVD) is defined as the number of proliferating vessels or 
endothelial cells in hot-spot areas of the tumor. MVD is an independent prognostic 
factor correlated to worse overall survival and disease free survival (DFS)119,181.  
Presence of tumor necrosis in primary melanomas was shown to be an independent 
prognostic marker182,183.  
Tumor-infiltrating lymphocytes (TIL) are assumed to be a favorable prognostic factor 
in terms of anti-tumor immune response since Clark et al.184 described a positive 
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association between the presence of TIL and better OS but their role as a prognostic 
marker is still discussed controversially179,185-187. 
The TNM staging system is used for all histologic subtypes85. In contrast to previous 
staging categories, all patients with microscopic melanoma metastasis in lymph nodes 
(lymphatic system) are classified as stage III. The number of positive nodes has 
significant prognostic impact as shown by Balch in the latest AJCC classification86. 
In patients with stage IV melanoma, the site of distant metastasis as well as LDH 
level has prognostic impact. Thus, patients with elevated LDH level are classified as 
M1c independently the localization of distant metastasis. The 2-year overall survival 
rate is 40% in patients with normal LDH compared to 18% in patients with elevated 
LDH86. 
Molecular markers 
Recently, a population based study including 912 patients did not find prognostic 
impact of BRAF or NRAS mutation status in primary melanomas on melanoma 
specific survival compared to wild-type tumors188. These findings confirm results 
from previously published studies78,189. Conversely, the presence of NRAS or BRAF 
mutations was reported as poor prognostic factors by others190-192. Ki67 and p53 
expression as well as loss of p16 expression were reported as independent prognostic 
markers193. In addition, protein as well as DNA and RNA-expression has been 
assessed in blood and tissue samples of melanoma patients to identify potential 
prognostic markers187,194-196. To date, LDH is the only one included in the AAJC 
staging system85. 
Clinical factors 
Age has been reported as an independent prognostic factor in several studies, even 
though various cut-off points to distinguish between younger and elderly patients 
were used197,198. Thicker and ulcerated melanomas were more often diagnosed among 
elderly patients; however, thickness and age were the only independent prognostic 
markers in a multivariate analysis by Austin et al.197. Age was also an independent 
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prognostic factor for OS within each thickness subgroup in the large dataset used for 
validation of prognostic factors by the AJCC in 2001199. 
Clark was the first who observed better prognosis among women compared to men in 
his publication from 196972. Gender has been determined as an independent 
prognostic factor in several studies during the last decades90,178. Joosse et al. 
confirmed a lower risk of progression in female patients with significantly reduced 
risk of visceral metastases compared to men and showed that the survival advantage 
persisted after progression of disease200. It looks like the survival benefit of women is 
independent of differences in detection or diagnostic delay as well as age at 
diagnosis, ulceration and female hormone-status200.  
A correlation between anatomic site and better outcome has been reported in several 
studies; melanomas on the limbs have in general better prognosis than those located 
on the trunk or head and neck198,199.  
1.6.2 Predictive markers 
The BRAFV600E mutation is the best established predictive marker with high response 
rates to treatment with BRAF inhibitors201. Furthermore, KIT mutated melanomas can 
be successfully treated with a KIT inhibitor202. The predictive value of programmed 
death-ligand 1 (PD-L1) expression is still under investigation. Sunshine and Taube 
found a correlation between PD-L1 expression by tumor cells and objective response 
in average 45% of  the patients with solid tumors treated with anti-PD-1 or anti-PD-
L1 inhibitors203. Since 15% of the patients with PD-L1 negative tumors responded to 
treatment, further investigation is needed to determine the role of PD-L1 as a 
predictive marker203 
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1.7 Treatment of melanoma  
1.7.1 Primary melanoma 
Surgical treatment  
Surgery is the gold standard in treatment of primary cutaneous melanoma. Excision 
of a suspicious lesion is the method of choice to obtain complete histologic 
diagnosis86,204. In case of melanoma, complete excision with adequate margins should 
be performed whereupon Breslow thickness is the determining factor.  Excision 
margins with up to 5 cm were common from the beginning of the last millennium 
until the 1970s205. Recommendations changed dramatically over time and current 
guidelines from Europe, America and Australia accepted much narrower margins as 
shown in Table 5206.  
Table 5. Recommended excision margins  
T stage by Breslow thickness 




Tis, in situ 0.5 cm 0.5 cm 
T1 < 1.0 mm 1.0 cm 1 cm 
T2 1.01 – 2.0 mm 1-2 cm 1 cm 
T3 2.01 – 4.0 mm 2 cm* 2 cm 
T4 > 4.01 mm 2 cm 2-3 cm 
NCCN: National Comprehensive Cancer Network; CCO: Cancer Care Ontario; CMA: 
Canadian Medical Association; ESMO: European Society for Medical Oncology; ANC: 
Australian Cancer Network. 
*except ANC: 1-2 cm. Table modified from Fong206; 1: Nasjonalt Handlingsprogramm94 
 
For in situ melanoma, there exists no randomized trial, so the recommendation is 
based on the consensus of an expert panel. Randomized trials that investigated 
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different margins in intermediate thickness melanomas (1-4 cm) did not find any 
difference in OS205,206; however, Thomas et al. found a higher rate of local recurrence 
among the group with 1 cm margins compared to the group with 3 cm margins207.  
An ongoing neo-adjuvant trial investigates the clinical and pathological response of 
the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor 
cobimetinib in patients with BRAF mutated melanoma with palpable lymph node 
metastases (clinicaltrials.gov NCT02036086).  
1.7.2 Treatment of regional lymph nodes 
Sentinel node biopsy is recommended for patients with melanoma thickness 1-4 mm 
as described above93.  
Any enlarged lymph node discovered by clinical examination or ultrasound should be 
biopsied for further diagnostics. Complete lymph node dissection should be 
performed if nodal metastases are confirmed and distant metastases were not 
detected204. Adjuvant radiotherapy after lymphadenectomy showed significant lower 
recurrence rates but increased morbidity without OS benefit. This treatment should 
therefore mainly be considered in patients with high risk nodal-disease206. 
1.7.3 Adjuvant treatment  
10-year survival rate is < 50% among patients with AJCC stage IIC, IIIB and IIIC86. 
As a consequence, several clinical trials have investigated treatment options for this 
patient group over the last decades. 
The efficacy of immune therapy has been evaluated for interferon alpha in several 
trials, testing low dose, high dose or pegylert interferon to improve the outcome for 
this patient group. Two recently published meta-analyses by Mocellin et al. showed 
improved DFS and OS for treatment with interferon alpha208,209. However, current 
guidelines do not agree about recommendation of adjuvant interferon alpha. This is 
probably caused by conflicting results about OS benefit in many studies206,210,211. 
Ipilimumab, an inhibitor of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), 
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was the first drug that showed improved OS in metastatic melanoma. Based on the 
encouraging results, this drug is also investigated in adjuvant trials. Recently 
published results from the randomized, placebo controlled EORTC 18071 trial 
showed significantly improved recurrence-free survival in patients with high risk 
stage III melanoma212.  However, 52% discontinued treatment with Ipilimumab, so 
risk-benefit, cost effectiveness and OS benefit should be evaluated in future. 
Ipilimumab and the PD-1 receptor inhibitor nivolumab are currently under 
investigation for adjuvant treatment (clinicaltrials.gov: NCT02388906, 
NCT02437279).   
Targeted therapy achieved encouraging response rates in patients with BRAF 
mutated metastatic melanoma. Recurrence free survival time of adjuvant treatment 
with the BRAF inhibitor dabrafenib (clinicaltrials.gov NCT01682213) or 
vemurafenib (BRIM8, clinical trials.gov NCT01667419) is currently tested.  
Since angiogenesis is important in tumor growth and metastases, the benefit of anti-
angiogenic treatment with bevacizumab monotherapy was investigated in high risk 
patients after complete resection. Interim analysis of this randomized phase III trial 
showed improved PFS in the treated group; data for the primary endpoint, OS benefit 
after 5 years, are pending213.  
1.7.4 Treatment of local recurrence 
In-transit metastases are lesions that occur > 2 cm from the primary melanoma and 
are seen in 4-14% of melanoma patients206. Solitary, localized lesions can be 
excised204 or treated locally with interferon alpha injections, topical application of 
imiquimod or radiotherapy206. Hyperthermic isolated limb perfusion (HILP) and 
isolated limb infusion (ILI) are other options in case of multiple lesions on the 
extremities214. Complete response rates are higher in HILP215 compared to ILI214,216; 
however, HILP is a more complicated and costly procedure with a higher right of 
adverse side effects.  In general, all mentioned therapies provide local disease control 
but no benefit in OS206.  
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1.7.5 Treatment of metastatic disease 
Five-year survival for patients with metastatic disease is poor and depends on 
localization of distant metastases and LDH level86. Targeted therapy and immune 
checkpoint blockade revolutionized the outcome of patients with stage IV melanoma 
dramatically after many decades without any drug that could improve OS and low 
response rates to available treatment options. 
Surgery  
Surgery can improve OS in all categories of stage IV disease if complete resection 
(R0) can be achieved, as shown in multiple studies for different metastatic sites. This 
approach should be considered in patients with solitary or few localized metastases 
and good performance status. Tumor volume doubling time within 60 days is a good 
marker to assess aggressiveness of metastases and should be taken in consideration 
when patients are selected for metastasectomy217.  
Targeted therapy 
BRAF is mutated in about 50% of melanomas, resulting in an upregulation of the 
MAPK pathway. BRAF inhibitors vemurafenib and dabrafenib were approved for 
treatment of metastatic melanoma in 2011 and 2013, respectively. Each of these 
drugs shows high response rates with improved PFS and OS compared to 
chemotherapy with dacarbazine in randomized phase III trials201,218-220. However, the 
curves for PFS in patients treated with vemurafenib and dacarbazine meet each other 
after about 20 months218 and converge to each other after about seven months in the 
dabrafenib study219. Acquired resistance is a major problem in treatment with BRAF 
inhibitors221-223. The MAPK pathway can be activated in an alternative manner by 
mutations in MEK or BRAF independent MEK activation. The efficacy of the MEK 
inhibitors trametinib and cobimetinib was tested as single agents as well as in 
combination with BRAF inhibitors. The combination therapy with BRAF and MEK 
inhibitors is superior to single drug treatment due to response rates, PFS and OS220. 
Furthermore, the number of cutaneous squamous cell carcinomas was lower among 
patients treated with combination therapy220. 
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To date, no targeted therapy for NRAS mutated melanomas is established. Promising 
results were observed in in a phase II study with the MEK inhibitor binimetinib, and a 
randomized phase III trial in NRAS mutated melanoma is ongoing224. Furthermore, 
early clinical trials for combination of MEK and CDK4 inhibition or MEK and 
PI3K/Akt inhibition are ongoing224. 
Immunotherapy 
Inhibition of key immune checkpoints was the first treatment that improved overall 
survival in patients with stage IV melanoma. The best known examples are inhibition 
of CTLA-4 and the PD-1 receptor on T-cells as well as the PD1 ligand (PD-L1) on 
the surface of tumor cells. These inhibitory receptors modulate the immune system 
independently from each other and their inhibition results in enhanced anti-tumor 
immune response and increased OS. CTLA-4 regulates T-cell proliferation and 
migration to the tumor; PD-1 and PD-L1 interact with T-cells at the tumor site225. 
Randomized controlled phase III studies demonstrated OS benefit for patients treated 
with ipilimumab226,227; in addition, durable long term survival benefit was seen for 
18-26% of the patients with a plateau from the third year228,229. Efficacy of PD-1 
inhibition was published for the first time in 2010230 and confirmed in another phase I 
study in 2012, in which response was seen in 1 out of 4 melanoma patients231. A 
recently published phase III trial comparing nivolumab with chemotherapy after 
progress on ipilimumab or a BRAF inhibitor showed a response rate of 38% in 
pretreated melanoma patients232. 
Combination of CTLA-4 and PD-1 inhibition in a phase I study showed promising 
response rates233 which were confirmed in a recently published randomized phase III 
trial234. Several studies combining ipilimumab and PD-1 or PD-L1 inhibitors as well 
as combinations of immunotherapy wit targeted or anti-angiogenic therapy are 
ongoing. To date, no predictive marker is established for any of the immune-
therapeutic options. 
Autologous tumor-infiltrating T-lymphocytes (TIL) are used in adoptive cell transfer 
immunotherapy. This treatment alternative showed objective response rates of about 
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50% in patients with metastatic melanoma and 20% of the responders had durable 
remissions235. Based on the promising results from clinical phase II studies, a 
randomized multicenter phase III trial is under development235.  
Chemotherapy 
Dacarbazine, an alkylating agent, is the only FDA approved chemotherapeutic agent 
for treatment of metastatic melanoma and it was widely used for many decades in 
lack of other treatment options. The overall response rate was about 15% in a meta-
analysis of randomized trials but OS benefit was never shown236. Today it is still a 
treatment option in BRAF wild type patients who do not respond to immune therapy. 
Patients with BRAF wild type had improved clinical benefit and overall survival in a 
single arm, single institution study with dacarbazine237. Temozolomide, orally 
administrated dacarbazine, shows overall response rates comparable to dacarbazine 
but penetrates into the CNS and is preferable in case of brain metastases236. Several 
other chemotherapeutic agents were tested as single drugs or in combination but none 
showed OS benefit238.  
Anti-angiogenic treatment 
Monoclonal antibodies as well as tyrosine kinase inhibitors have been investigated 
for anti-angiogenic treatment of metastatic melanoma239-241. Bevacizumab, a 
humanized monoclonal antibody against VEGF-A, was investigated in combination 
trials and as single agent. Monotherapy did not meet the primary objective in a 
randomized study by Varker et al.242. Addition of bevacizumab to chemotherapy 
showed favorable outcomes, but significant benefit could not yet be confirmed. In the 
BEAM trial that compared chemotherapy alone versus chemotherapy and 
bevacizumab, OS was significantly longer in the combination group (12.3 vs 8.6 
months), but follow up analyses after four additional months could not confirm the 
survival benefit. Furthermore, non-significant benefit in PFS was seen among the 
patients with combination therapy243.  
Interferon alfa (IFN α) has anti-angiogenic activity in low doses; IFN α in non-
cytostatic concentrations down-regulated bFGF concentration and angiogenesis in 
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vitro and in vivo244,245. Furthermore, successful treatment of pediatric hemangiomas 
was described246. In melanoma, IFN α did not show any additional benefit when 
given together with bevacizumab242.  
1.8 Clinical studies 
1.8.1 Classification of clinical studies 
There exist four different types of clinical studies: phase I, phase II, phase III and 
phase IV-trials. In phase I trials the new drug is given to a small number of patients in 
increasing dosage to find the maximum tolerable dose, the most favorable application 
schedule and to describe the toxicity profile247. Because of the toxicity of cancer 
drugs, all testing is done in patients and not in healthy volunteers. Pharmacokinetic 
and pharmacodynamics parameters are assessed in addition248. 
Safety and potential efficacy of the new drug are investigated in phase II studies. 
Since sample size is limited, efficacy should be validated in lager randomized phase 
III studies247. 
Phase III trials are conducted to confirm efficacy of the drug of interest and to record 
the incidence of adverse events in a greater number of patients. Usually, the trials are 
randomized and often stratified to ensure balanced groups. “Comperative efficacy 
trials” assess the question if the new drug improves outcome compared to current 
standard treatment or placebo247. “Equivalency trials” are another type of phase III 
studies. They investigate if the new drug is equivalent to the established treatment247. 
1.8.2 Response evaluation 
Changes in tumor burden are assessed clinically or radiologically to evaluate 
response to treatment. The response evaluation criteria in solid tumors (RECIST)-
guidelines are an important tool in this process and secure that the same criteria are 
used globally. These response evaluation criteria in solid tumors were published in 
2000 for the first time and updated in 2008249. Since the clinical effects of new 
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immune therapeutics cannot necessarily be adequately evaluated by the classical 
RECIST criteria, new immunological response criteria were suggested250. 
1.8.3 Evaluation of critical adverse events 
Critical adverse events (CAE) that occur during investigation of a new drug in 
clinical trials must be recorded continuously and are reported in the safety profile of 
the study. These criteria are published by the National Cancer Institute and are 
regularly updated251. In the protocol of every clinical trial, it has to be defined which 
version of the Common Terminology of CAE (CTCAE) is used. Critical events are 
graded from 1 (asymptomatic or weak symptoms) to 5 (death).  
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2. PURPOSE OF THE STUDY 
2.1 General aim 
When this clinical phase II trial was initiated at Haukeland University Hospital, 
chemotherapy was the only established treatment for patients with metastatic 
melanoma. During recent years, new drugs have become available and high response 
rates to BRAF inhibitors and various treatment options, including immune checkpoint 
blockade, show promising results220,228,234,252. However, there are still limited 
treatment options for patients who are not suitable for immunotherapy, do not 
harbour the BRAF mutation or progressed to first line treatment. The aim of this 
thesis was to investigate the efficacy of anti-angiogenic treatment with bevacizumab 
monotherapy in patients with metastatic melanoma and to identify potential 
predictive markers. 
2.2 Specific aims 
1. To investigate efficacy and safety of treatment with bevacizumab monotherapy 
in patients with metastatic melanoma in a clinical phase II study (Paper I).  
 
2. To examine the predictive value of angiogenesis related markers in tissues and 
blood samples of patients treated with bevacizumab monotherapy, and to study 
the correlation between angiogenesis markers (MVD, pMVD, GMP) and 
treatment response (Paper II).  
 
3. To analyze serum samples by a multiprotein array to identify potential 
predictive markers, and to perform further validation by single protein assays 
in blood samples and by immunohistochemistry in metastases (Paper III). 
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3. MATERIALS AND METHODS 
3.1 Study design and ethics 
The PhD-project is based on a clinical phase II trial (ClinicalTrials.gov 
NCT00139360) run at the Oncology Department at Haukeland University Hospital in 
Bergen, Norway. This study is an open labeled, single arm, single institution clinical 
trial where patients with metastatic melanoma in progression were treated with 
bevacizumab monotherapy until disease progression or intolerable toxicity. The 
dosage of the drug was 10mg/m2, given every 14 days. Computer tomography (CT) 
was performed every 8th week for response evaluation. Biopsies and blood samples 
for research purposes taken before the first treatment were investigated. The study 
design was based on the two-stage design for clinical phase II trials by Simon253. 
Response of the study drug had to be shown in patients that progressed on standard 
treatment before bevacizumab could be given first line. The study was approved by 
the regional ethic committee (processing number: 05/329) and was conducted in 
accordance with the ethical principles of the Declaration of Helsinki and the 
International Conference on Harmonization of Good Clinical Practice. All patients 
signed informed consensus before enrollment. 
3.2 Patients  
52 patients at Haukeland University Hospital were screened for inclusion in the study 
between April 2005 and March 2010. Eligibility criteria are listed in Table 6, more 




Table 6. Eligibility Criteria 
Inclusion Criteria Exclusion Criteria 
Histologically confirmed metastatic 
disease in progression 
more than 1 prior chemotherapy regimen 
for metastatic disease 
WHO-performance status 0-2 
prior interferon alpha or IL-2 for 
metastatic disease 
Age >18 years pregnant or lactating patients 
Able to undergo outpatient treatment clinical evidence of coagulopathy 
Clinically and/or radiographically 
measurable disease according to RECIST 
psychological, familial, sociological or 
geographical condition potentially 
hampering compliance  
>4 weeks since adjuvant interferon alpha brain metastases 
Recovered from prior chemotherapy symptomatic congestive heart failure 
absolute granulocytes > 1.0 x 109/L 
unstable angina pectoris or cardiac 
arrhythmia 
platelets > 100 x 109/L history of thrombosis 
bilirubin < 1.5 x upper normal limit 
non-steroidal anti-inflammatory 
medications 
Normal serum creatinine uncontrolled hypertension 
INR < 1.5 
full-dose anticoagulants (INR>1.5) or 
heparin, or daily treatment with aspirin 
(>325 mg/day) 
 
3.3 Response assessment and toxicity 
Treatment response was evaluated according to RECIST published in 2000254. Main 
outcome measures were complete response (CR), partial response (PR), stable disease 
(SD) and progressive disease (PD). Measurement is based on the longest diameter of 
target lesions and response is defined by the relative change in the sum of these 
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diameters. In case of CR, the target lesion has completely disappeared. PR is 
achieved when the sum of target lesion diameters decreased at least 30%. On the 
other hand, PD is reported when the sum increases by at least 20%254. Best overall 
response (BOR) is the best response observed between treatment start and disease 
progression. Based on these criteria, we defined different types of responses. 
Objective response (OR) includes CR and PR; this was the primary endpoint in the 
study. Disease control (DC) describes patients with CR, PR or SD for at least 6 
months. BOR is not applicable in patients who progressed clinically before first CT 
evaluation. Time to progression (TTP) is defined as the time from enrolment to PD or 
death due to melanoma. Progression free survival (PFS) is the time from inclusion 
until PD. Overall survival (OS) is the time from inclusion until death. Response status 
by August 2011 was reported in Paper I and II; in Paper III, the observation time 
was extended to September 2013. 
Critical adverse events were graded according to CTCAE, version 3.0 defined by the 
National Cancer Institute251 and were recorded every 2nd week. Early hypertension 
(EH) was defined as hypertension ≥ grade 1 according to CTCAEv3.0 diagnosed 
before the first response evaluation at eight weeks. 
3.4 Sampling of tissue and blood samples 
Paraffin-embedded tissue from 32/35 primary tumors was obtainable for 
immunohistochemically staining as performed in Paper II. The three missing blocks 
included one patient with unknown primary tumor, one patient with ocular melanoma 
treated with brachytherapy and one not trackable tissue block. Because of insufficient 
material, 30/35 primary tumors were available for immunohistochemical 
investigations in Paper III. Furthermore, 35/35 metastases were accessible for 
analyses. If several biopsies were taken at various time points, the metastasis 
diagnosed closest to date of inclusion was chosen (median 5 days). Core needle 
biopsies mainly taken from lung, liver, abdominal or pelvic organs were taken in 
17/35 patients. In addition, 18/35 excisional biopsies from skin metastases or lymph 
nodes were available.  
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Furthermore, blood samples were taken before the first treatment with bevacizumab 
(median 2 days). From the 35 patients, 28 serum samples and 29 plasma samples 
were collected at baseline. Serum samples were taken in 10 ml gel free tubes. After 
clotting for 30 minutes, the tube was centrifuged at 1600 x g for 10 minutes at 4°C 
and plasma was frozen at -20°C. Plasma samples were taken in EDTA-tubes, 
centrifuged at 1600 x g for 10 minutes at 4°C and plasma was frozen at -20°C. Blood 
samples were aliquoted when used for analysis for the first time. In addition, routine 
samples including LDH were taken from all patients at time of inclusion and before 
every new cycle. 
3.5 Clinico-pathologic variables 
The following variables were recorded: anatomical site of primary tumor and of 
metastasis, sex, age, WHO performance status, M-stage, number of previous 
treatment lines for metastatic disease, presence of proteinuria, diagnosed 
hypertension before enrollment, blood pressure before treatment start and before 
every further treatment with bevacizumab, anti-hypertensive medication used at time 
of inclusion and changes during treatment with bevacizumab. Furthermore, the 
number of treatment cycles with dacarbazine and/or bevacizumab was recorded.  
Hematoxylin and eosin-stained sections from all primary melanomas were 
reclassified by LAA and CS blinded for response data. The following histopathologic 
features were reported: histologic type72,73, thickness by Breslow87, ulceration88, 
mitotic rate86,90, Clark level of invasion72, growth phase184, presence or absence of 
vascular invasion255, regression184 and necrosis183 as well as tumor infiltrating 
lymphocytes (TIL) categorized as absent, non-brisk or brisk184,256. In addition, the 
presence of TIL in metastases was recorded by OS and CS in hematoxylin and eosin-
stained sections from metastases.  
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3.6 Analysis of mutation status 
Direct Sanger sequencing was used for BRAF and NRAS mutation screening. Tumor 
tissue was manually dissected from three paraffin sections (10μm), followed by 
DNA-extraction with the E.Z.N.A. Tissue DNA Kit (Omega Bio-Tek, Inc., Norcross, 
GA, USA). Amplifying of BRAF exon 11 and 15 and NRAS exon 1 and 2 by PCR 
was performed with previously described primers. The sequence reactions were done 
with the Terminator Cycle Sequencing kit, BigDye version 1.1 (Applied Biosystems, 
Foster City, CA, USA), and were analyzed on an ABI PRISM 3100 Genetic analyzer, 
applying Sequencing Analysis software, version 3.7 (both from Applied Biosystems).  
3.7 Immunohistochemistry 
Immunohistochemical staining was performed on 4-5μm thin tissue sections from 
primary melanomas and metastases. Mono staining was done with primary antibodies 
for HSP27, VEGF-A, VEGF165b, bFGF, anti-factor VIII (F-VIII), uPAR, Activin-A 
and IL1b. In addition, double staining with F-VIII and Ki67 was performed for 
assessment of angiogenesis. First, the sections were deparaffinized in xylene and 
different alcohol dilutions. After rehydration, antigen retrieval was performed by 
proteinase K, heating the specimens in the microwave or the pressure cooker. 
Endogenous enzyme activity was inhibited by blocking with peroxidase inhibitor, 
dual endogenous enzyme block or protein block before incubation with the primary 
antibody. A detailed overview including detection antibodies and chromogens is 
provided in Table 7. Tissues from different cancer types were used as positive 
controls. For negative controls, primary antibodies were omitted or specific blocking 
peptides, for HSP27, VEGF-A and bFGF, were used.  
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Table 7. Immunohistochemical staining methods 
Antibody Provider Epitope retrieval Dilution Incubation 
HSP27 pAb sc-1048 (goat) Santa Cruz MW 6
th sense 20 
min, pH6 1:100 30 min, RT 
VEGF-A pAb sc-152 (rabbit) Santa Cruz MW 6
th sense 20 
min, pH9 1:50 60 min, RT 
VEGF165b mAb ab14994 
(mouse) Abcam 
MW 6th sense 20 
min, pH9 1:100 Overnight, 4°C 
FGF-2 pAb sc-1390 (rabbit) Santa Cruz Pressure cooker, pH9 1:50 60 min, RT 
Von Willebrand Factor pAb 
A0082 (rabbit) Dako Proteinase K, 5 min 1:800 30 min, RT 
Von Willebrand Factor pAb 






1:200 60 min, RT 
Activin A pAb A-1594 (goat) Sigma Aldrich MW 6
th sense 
20min, pH8 2,5μg/ml 60 min, RT 
IL1b pAb sc-7884 (rabbit) Santa Cruz MW 6
th sense 
20min, pH6 1:50 120 min, RT 




MW 6th sense 
20min, pH6 1:100 Overnight, 4°C 
pAb: polyclonal antibody; mAb: monoclonal antibody; MW: Microwave;  
RT: Room temperature 
 
3.8 Evaluation of staining results 
For evaluation of immunohistochemical staining, sections were subjectively screened 
in a light microscope to avoid areas of ulceration, necrosis or scarring within the 
tumor. Cytoplasmic staining intensity was recorded for VEGF-A, VEGF165b, HSP27, 
bFGF, uPAR, IL1b and Activin A, nuclear staining was additionally recorded for 
bFGF and VEGF165b. Furthermore, the proportion of positive tumor cells, 
respectively endothelial cells in case of VEGF-A were recorded. Staining intensity 
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was graded as absent (0), weak (1), moderate (2) or strong (3)257. The proportion was 
rated as “no positive tumor cells” (0), “less than 10% positive tumor cells” (1), “10-
50% positive tumor cells” (2) or “more than 50% positive tumor cells” (3). The 
staining index (SI) is the product of intensity and area, ranging from 0-9; SI was 
evaluated by two observers (CS, OS) blinded for response data.  
3.9 Assessment of angiogenesis markers 
Microvessel density (MVD) was assessed as described by Weidner258 on sections 
double stained for F-VIII and Ki67. Thereby, we focused on areas with high intensity 
of F-VIII, defined as hot-spot areas258. Ulcerated and necrotic parts within the tumor 
were avoided. In addition, the number of proliferating microvessels (pMVD) was co-
registered in the same high power fields (HPFs). Proliferating vessels co-express 
Ki67 in the nucleus and F-VIII in the cytoplasm of endothelial cells (ECs)259. Finally, 
the vascular proliferation index (VPI) was calculated as the ratio between pMVD and 
MVD (%)259. MVD and pMVD were reported as the number of microvessels per 
mm2. Sections were screened for hot-spot areas at magnifications x40 and x100; 
counting of MVD and pMVD was performed at magnification x400 in three HPFs. 
Glomeruloid microvascular proliferations (GMPs) are focal glomerulus-like 
aggregates of at least 15 related, multilayered F-VIII positive ECs. Presence or 
absence of GMPs was recorded in sections stained with F-VIII and hematoxylin at 
magnification x100 in four consecutive HPFs260,261. Assessment was done 
simultaneously by OS and CS blinded for response data. 
3.10 Analysis of blood samples 
3.10.1 Enzyme linked immunosorbent assay (ELISA) 
ELISA-kits based on the sandwich technique with pre-coated antibodies were used to 
measure the concentration of VEGF-A165 (DVE00 by R&D), HSP27 (ADI-EKS-500 
by Enzo Life science), bFGF (DFB50 by R&D), uPAR (DUP00, R&D) and Activin 
A (DAC00B, R&D) in serum, respectively plasma samples. The assays were 
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performed according to the manufacturer’s manual and the absorbance was measured 
at the wavelength of 450nm in a microplate reader (ELx808, Absorbance Microplate 
reader, BioTek Instruments, Inc.) immediately after the stop solution was added. All 
samples were run in duplicates. If the measured absorbance was above the highest 
standard, samples were diluted until they fit into the standard absorbance. Final 
sample concentrations that were below the minimal detection dose (MDD) as defined 
in the manufacturer’s manual were handled as zero measurements.  
3.10.2 Multiplex array 
This quantibody array (Quantibody Human Angiogenesis Array 1000, RayBiotech, 
Inc. Norcross/GA, USA) contains 60 angiogenesis-related proteins that are spotted on 
glass slides as quadruplicates. Briefly, all wells were blocked with sample diluent 
before incubation with serum samples for two hours. Washing was followed by 
incubation with the detection antibody and finally, Cy3 equivalent was added. When 
the slides were completely dry, imaging was done with a microarray scanner 
(GenePix 4000B, Axon Instruments) at different photomultiplier tube gains. 
Interslide normalization for the most suitable scan was performed by RayBiotech.  
3.11 Statistics 
As mentioned above (3.1), the trial design was based on the two-stage clinical trial 
design by Simon253 to determine sample size. The calculation was based on a 10% 
type I error rate and 90% power, and the assumption that treatment with bevacizumab 
would have a CB rate of 30%. These conditions required a minimum sample size of 
35 patients.  
Statistical analyses were performed with SPSS, version 22 (SPSS Inc., Chicago). 
Pearson’s chi-square test was used for comparison of two categorical variables. Non-
parametric tests were used for all analyses since not all data followed normal 
distribution. Associations between ordinal or continuous variables and categorical 
variables were assessed by Mann-Whitney U Test (MWT) or the Kruskal-Wallis Test 
(KWT). Paired Mann-Whitney Test (pMWT) was used to calculate the association 
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between proteins in the primary tumor and metastases by the assumption that these 
samples are matched pairs. Strength and direction of correlations between two 
interval scaled continuous or ordinal variables or one of each type were investigated 
by Spearman’s rho correlation. Kaplan-Meier curves were constructed for time-to-
event endpoints such as PFS and OS, and significance in differences was calculated 
by log-rank test. The significance threshold was 0.05 for all tests. When continuous 
variables were categorized, the median was used as cut point if not described 
elsewise. 
Log2 and quantile normalization was performed in serum concentrations from the 
multiplex array262. Outliers were detected by Dixon test. Then, unsupervised Ward 
hierarchical clustering was performed. Finally, supervised analysis of particular 
proteins was conducted. 
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4. MAIN RESULTS 
Paper I 
The efficacy and safety of bevacizumab monotherapy in patients with metastatic 
melanoma in progression was investigated in a clinical phase II study. 52 patients 
were screened and 35 were finally enrolled. 14/35 patients were treated with 
dacarbazine before inclusion in the study. One of those patients was previously also 
included in a study that assessed the efficacy of dacarbazine and ipilimumab. In 21/35 
patients, bevacizumab was given in first line. BRAF mutations were detected in 46% 
and NRAS mutations in 26% of the samples. 
6/35 patients (17%) showed objective response (OR) to treatment with bevacizumab; 
1/6 had complete response (CR) and 5/6 had partial response (PR). In addition, five 
more patients had stable disease (SD) > 6 months. In total, 31% of the patients had 
disease control (DC) and 69% (24/35) had progressive disease (PD). The treatment 
was well tolerated, no treatment related deaths occurred. However, bevacizumab had 
to be stopped in three patients according to grade 3 and grade 4 toxicities as defined 
in CTCAEv3.0. In addition, treatment had to be interrupted in one patient with 
symptomatic grade 3 toxicity. Hypertension according to CTCAEv3.0 was diagnosed 
in 14/35 patients after treatment with bevacizumab started. Early hypertension (EH) 
was significantly associated with DC, PFS and OS. Furthermore, all patients with 
stage M1a or M1b disease (7/7) had DC to treatment with bevacizumab compared to 
4/28 patients with stage M1c disease. Normal levels of LDH were correlated to DC. 
BRAF or NRAS mutation status, age, sex or performance status were not correlated 
with response to treatment. 
Paper II 
In Paper II, we investigated the potential predictive value of angiogenic factors in 
blood and tissue samples for response to bevacizumab monotherapy. Tissue 
expression of vascular endothelial growth factor (VEGF-A), the anti-angiogenic 
splicing variant VEGF165b, basic fibroblast growth factor (bFGF) and heat shock 
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protein 27 (HSP27) was investigated by immunohistochemistry. In addition, 
microvessel density (MVD), proliferating microvessel density (pMVD), vascular 
proliferation index (VPI) and the presence of glomeruloid microvascular 
proliferations (GMPs) were recorded. Strong cytoplasmic expression of HSP27 in 
tumor cells of metastases was correlated with objective response (OR) to 
bevacizumab monotherapy (p=0.044, MWT). Furthermore, disease control (DC) was 
seen among patients with strong HSP27 expression in primary melanomas. MVD was 
significantly higher in primary melanomas of patients with DC compared to non-
responders (p=0.042, MWT). Serum concentration of VEGF-A, bFGF and HSP27 as 
well as intratumoral expression of the other angiogenic factors was not associated 
with response to bevacizumab. 
Paper III 
The purpose of this paper was to detect angiogenic factors in serum samples that 
could predict treatment response to bevacizumab monotherapy. A multiplex protein 
array was used to identify candidate proteins in baseline samples. Fold-change 
differences between responders and non-responders were calculated based on their 
serum concentrations. To validate our findings, candidate markers were further 
assessed in single ELISA assays, and their tissue expression in metastases was 
investigated by immunohistochemistry. Relevant proteins investigated in Paper II 
were included in the analyses. Serum concentration of Activin A, IL1b, uPAR and 
VEGF-A was associated with response to treatment when assessed by multiplex 
array, but these findings could not be validated by ELISA. Strong intratumoral tissue 
expression of Activin A, IL1b and uPAR in metastases was associated with response. 
Furthermore, we found a correlation between the number of proliferating vessels and 
tissue expression of Acitvin A, IL1b and uPAR. These findings indicate that those 
proteins are involved in VEGF-A related angiogenesis and are potential predictors for 
treatment with bevacizumab monotherapy in patients with metastatic melanoma.  
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5. DISCUSSION 
5.1 Discussion of materials and methods 
5.1.1 Patients, study design and samples 
This was a single arm, single institution trial to show the effectiveness of 
bevacizumab monotherapy in an era where dacarbazine was the only established 
treatment for patients with metastatic melanoma. Fifty-two patients were screened 
and finally, 35 patients were enrolled in this clinical phase II study. The relatively 
high number of screening failures was due to brain metastases, co-morbidity or 
withdrawal of informed consent. Brain metastases were defined as exclusion criteria 
for treatment with bevacizumab because of increased risk for bleedings. Nevertheless, 
the number of patients needed to show benefit of bevacizumab monotherapy 
compared to dacarbazine was reached. Since this was a single center clinical trial and 
the number of screening failures was relatively high, the inclusion time ranged from 
2005 to 2010. A clear advantage of this study is the availability of matched primary 
tumors and metastases, blood samples, clinical data and follow-up data. 
To be able to investigate predictive markers that are specific to VEGF targeted 
treatment, the administration of bevacizumab as single drug was chosen. In many 
other studies in melanoma and other cancer types243,263-266, bevacizumab was given in 
combination with chemotherapy. This complicates the identification of predictive 
markers for anti-angiogenesis treatment. However, candidate markers that were 
identified will have to be validated in randomized trials before they can be introduced 
to clinical practice.  
For ethical reasons, the two step design by Simon was used. 14/35 patients were 
treated with dacarbazine first line before inclusion in the study. One of the 14 patients 
was originally included in a clinical study with dacarbazine +/- ipilimumab and 
continued with dacarbazine monotherapy before bevacizumab was given. When 
efficacy of treatment with bevacizumab monotherapy was shown in these patients, 
treatment with bevacizumab was given first line in the remaining 21/35 patients. The 
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study investigated efficacy of bevacizumab monotherapy in patients with metastatic 
melanoma in progression. Response evaluation was therefore performed in the total 
number of patients regardless of the line of treatment. Since treatment with 
dacarbazine may have influenced tumor biology 267, differences in protein expression 
between treatment lines were investigated intratumoral and in serum samples and 
descriptive data were reported. 
5.1.2 Immunohistochemistry 
All antibodies were first tested on whole tissues sections of melanomas, tissue 
recommended as positive controls and tissue microarrays containing cores of various 
normal tissues as well as different tumor tissues. The time of tissue fixation in 
formalin is an unknown variable when working with archival paraffin embedded 
tissue blocks. Different fixation times can result in inhomogeneous 
immunohistochemical staining. To optimize demasking of the epitopes, different 
retrieval methods like proteinase K, cooking in different buffers with pH 6, pH 8 or 
pH 9 and heating in the microwave or the pressure cooker, were tested. To determine 
the best staining for each antibody, different dilutions of the primary antibody as well 
as varied incubation times were used. Endogenous phosphatase or peroxidase was 
inhibited prior to incubation with the primary antibody. Detection systems based on 
alkaline phosphatase (AP) or horseradish peroxidase (HRP) in combination with 
different chromogens were tested. 3-Amino-9-ethylcarbazole (AEC) was preferable 
used for visualization in HRP-based staining protocols. Final counterstaining with 
hematoxylin was applied when mono-staining was performed. Biopsies that easily 
fell off the glass slides during the staining process were incubated at 58°C degrees 
overnight.  
5.1.3 Evaluation of staining methods and assessment of 
angiogenesis markers 
Immunohistochemical staining was evaluated in a semiquantitative manner as 
described in chapter 3.8. For HSP27, VEGF-A and bFGF assessment was done 
simultaneously at a double light microscope by CS and OS. The other factors were 
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rated by CS and indistinct cases were discussed with OS. The amount of 
representative tumor tissue was sparse in some of the core needle biopsies from 
metastatic lesions, though biopsies were taken in accordance with contemporary 
clinical practice. The intratumoral staining for HSP27, VEGF-A and bFGF could be 
evaluated in all metastases. Due to the limited amount of tumor tissue in some 
samples, staining for VEGF165b and uPAR could be evaluated in 34/35 metastases, 
staining for IL1b in 33/35 and staining for Activin A in 32/35 metastases.  
Recording the intratumoral protein expression by the SI as described, takes both the 
intensity and the area of protein expression into account. This method may capture 
protein expression more completely than recording the staining intensity only. This 
index is established as a robust method in our group. However, the lack of 
standardized staining protocols and the multitude of various manual and digital 
evaluation methods are important issues when results from different studies are 
compared.  
Assessment of MVD and pMVD was performed as described in chapter 3.9. Before 
recording MVD in patient samples, counting of MVD and pMVD was practiced in a 
series of colon cancer sections stained for CD31, F-VIII and F-VIII/Ki67. The MVD 
and pMVD count in this test material was recorded by experienced colleagues 
previously, so that the inter-observer agreement by kappa and Spearman`s rho could 
be calculated. When satisfactory kappa and Spearman`s rho correlation was achieved 
for intra- and inter-observer correlations in the colon series, assessment in the patient 
samples was performed by CS. Due to the limited amount of tissue in small primary 
tumors and several needle biopsies of metastases, three HPFs were chosen to 
determine MVD and pMVD in hot-spot areas. Difficult cases in the patient samples 
from the melanoma series were evaluated together with OS. Two of the 35 metastases 
contained insufficient amount of material to evaluate three representative high power 
fields, so MVD and pMVD were reported in 33/35 cases.  
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5.1.4 Analyses of blood samples 
The choice of sample type is an important issue already in the planning phase of a 
clinical study. The sampling protocol should be as standardized and simple as 
possible to make sure that there is little variation in handling of the samples at this 
stage. Advantages and disadvantages of additives in various tubes should be taken 
into consideration because they can be an issue in later analyses. The use of serum 
samples eludes this problem but proteins can be bound or released by different cells 
during clotting. It is for example shown that VEGF is released by platelets and that 
this process results in significantly higher serum concentrations of VEGF compared 
to plasma concentrations268,269. Our results were in line with this, when VEGF was 
measured in EDTA plasma and serum samples. However, low VEGF-A 
concentrations in plasma samples can be below the detection limit of the assay. In our 
material, all serum samples were within the detectable range but 6/29 plasma samples 
had to be handled as zero measurements. As discussed by George et al.270, serum may 
therefore be the preferable sample type anyway. However, biomarker analyses have 
been performed in various types of blood samples271,272; this may be one reason why 
still no predictive markers for treatment with bevacizumab have been established.  
Furthermore, ELISA kits from different manufacturers are pre-coated with different 
antibodies resulting in various detection sensitivity and different final protein 
concentrations. Commercial ELISA kits are often not established in research with 
human samples and sensitivity for binding the protein of interest in such samples may 
not be high enough, especially if the expected concentration is low. In single protein 
ELISA, reactivity of the kit with the antigen is visually traceable and cross reactivity 
is less relevant. However, up to 240μl sample or more can be needed to analyze one 
protein in duplicate and insufficient binding of the antigen to the antibody epitope can 
be problematic. In the Quantibody array, less than a third part of sample volume was 
sufficient to perform the assay in quadruplicates. Another advantage was the 
possibility to perform multiple scans to figure out the best adjustments of the laser 
scanner for most of the proteins. Though, finally one scan had to be chosen for 
interslide normalization and further analyses. Since different detection methods and 
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different antibodies were used in ELISA and the multiplex array, the final 
concentrations of proteins assessed by both methods were not necessarily correlated. 
This demonstrates once more the difficulties in detecting reliable validated predictive 
markers.  
5.1.5 Statistics 
As mentioned in chapter 3.11, the sample size was calculated to show efficacy of 
bevacizumab monotherapy in patients with metastatic melanoma. The analyses of 
predictive markers have to be interpreted with caution due to low sample size and the 
findings need to be validated in a larger randomized study. At the same time, some 
analyses may not have been able to detect existing differences between responders 
and non-responders.  
The choice of cut-off points in continuous variables like the staining index is also an 
issue of discussion. We used the Mann-Whitney U test to distinguish between 
responders and non-responders. However, when predictive markers should be used in 
clinical practice, the definition of a cut-off point will be necessary.  
We did not correct for multiple testing. In Paper II, the analyses were performed 
based on pre-specified hypotheses. The candidate proteins we investigated were 
involved in VEGF-A related angiogenesis and treatment with a VEGF-A inhibitor 
was given. Paper III was based on a boarder screening approach to identify potential 
predictive markers. However, the sixty proteins investigated by the multiplex array 
were angiogenesis related. Potential candidate proteins were further validated by an 
additional test method like single ELISA assays or immunohistochemistry. 
5.2 Discussion of results 
5.2.1 Angiogenesis and anti-angiogenic treatment in melanoma 
Tumor growth beyond a few square millimeters and metastatic progression depend on 
angiogenesis100,110,273. Activation of the angiogenic switch seems to play a role in the 
transition from horizontal to radial growth phase in primary melanomas274. 
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Furthermore, increased vascularization was shown to be an adverse prognostic factor 
for OS120,176,275. In addition to these studies in archival material and preclinical 
models276,277, Srivastava et al. measured the Doppler flow signal in primary 
melanomas278. A recently published study with 15 years follow up time reported 39% 
melanoma related cases of death in patients with Doppler flow positive primary 
lesions compared to no melanoma related deaths and no recurrences in the Doppler 
flow negative group278. Conversely, others did not show any correlation between 
angiogenesis and melanoma outcome279,280.  
However, multiple clinical trials investigated various anti-angiogenic treatment 
options as referred to in chapter 1.7. In our material, 6/35 patients with metastatic 
melanoma in progression had objective response (OR) to bevacizumab monotherapy; 
in addition, 5 more patients had stable disease (SD) for at least 6 months (Paper I). 
One patient had complete response (CR) and is still disease free without receiving 
further treatment. These findings are in contrast to the results from Varker et al.242 
who observed no partial or complete response in patients treated with bevacizumab 
monotherapy. This may be explained by the low sample size (n=16). An overall 
response rate of 17%, as reported in our material, is in line with the findings of other 
studies combining bevacizumab with fotemustine (OR 15%)281, temodalozide (OR 
16%)282 or dacarbazine (OR 19%)283. A similar overall response rate (19%) was also 
reported after monotherapy with the selective VEGF-R inhibitor axitinib284. When 
bevacizumab is given in combination with carboplatin and paclitaxel, higher overall 
response rates were achieved (33%)263, 25.5%243).  
Development of early hypertension (EH), i.e. before the first evaluation, predicted 
response to treatment (Paper I) and was observed in 63.6% of all responders (7/11) 
compared to 12.5% of the patients with disease progression. Among the responders, 
4/6 patients with overall response developed EH. The median progression free 
survival time and overall survival were significantly longer in patients with EH 
(Paper I). Also among patients with metastatic melanoma who were treated with the 
VEGF-R inhibitor axitinib, induced hypertension predicted better PFS and OS284. 
Bevacizumab-induced hypertension was also predictive for outcome in several other 
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studies in that bevacizumab was given in combination with other drugs; even though, 
some findings were contradictory285. The controversial findings could be explained 
by various time points and techniques of blood pressure measuring, various 
definitions of hypertensive events, differences in anti-angiogenic treatment and 
different tumor types. Lambrechts et al. investigated VEGF-A pathway and 
hypertension associated SNPs in a pooled analysis from patients receiving 
bevacizumab-containing treatment. Several candidate markers were identified; 
however, statistical significance was not maintained after correction for multiple 
testing286. In general, it is not unproblematic to use an adverse event like hypertension 
as predictive biomarker as discussed by Jubb et al.285. Adverse events may become 
severe, need additional treatment or result in interruption or termination of treatment. 
Therefore, upfront predictive markers are preferable to avoid starting ineffective 
therapy. 
Normal LDH and M1a or M1b-stage were other predictive factors in our material. 
The correlation between a normal level of LDH at baseline and better response was 
also reported by Fruehauf et al.284. Furthermore, the level of LDH and M-stage are 
well established prognostic factors86 and characterize less aggressive melanomas. We 
did not find any correlation between the BRAF or NRAS mutation status and response 
to treatment. So, anti-angiogenic treatment could be an option for BRAF wild type 
patients who are not eligible for immunotherapy or patients who progressed on first 
line treatment with BRAF inhibitors or immune modulating drugs. A recently 
published phase II trial showed significantly better OS in BRAF wild type patients 
compared to BRAF mutated patients treated with axitinib and subsequently 
administration of paclitaxel/carboplatin287.  
5.2.2 Candidate markers of angiogenesis 
VEGF-A plays an important role in physiologic and pathological angiogenesis by 
activation of endothelial cell proliferation and migration, and promotion of vessel 
dilatation and permeability126. VEGF-A and its receptors are not expressed in normal 
melanocytes but are overexpressed in melanoma cells279,280,288. We observed 
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intratumoral VEGF-A expression in nearly all primary melanomas and metastases 
(Paper II). The quantification of protein expression did not correlate with response to 
treatment with bevacizumab monotherapy. Since VEGF-A is a ligand, it can be 
intracellular, extracellular or receptor bound. Because of the ubiquitous existence of 
ligands, it is more difficult to quantify their presence and biological activity 
compared to proteins that are exclusively seen in a particular cellular compartment. 
However, in primary melanomas, strong VEGF-A expression was correlated to a 
higher number of proliferating vessels (pMVD) and in metastases, VEGF-A 
expression was associated to a higher number of microvessels (MVD) (Paper II). 
These findings confirm a role of VEGF-A dependent angiogenesis in a subgroup of 
primary melanomas and metastases. VEGF-A contributes also to angiogenesis by re-
localization of uPAR to the leading edge of migrating endothelial cells144,289. In our 
material, strong intratumoral uPAR expression in metastases was associated to better 
OR, a higher MVD, presence of GMPs and stronger expression of HSP27 in 
metastases (Paper III).  
In addition to VEGF-A, we investigated expression of the anti-angiogenic splicing 
variant VEGF165b. This isoform binds to bevacizumab with the same affinity as 
VEGF-A290 and is strongly expressed in normal tissue but seems to be down-
regulated in tumors127,280,291. In primary melanomas that metastasized, no expression 
of VEGF165b was recorded, even though it was expressed in peritumoral normal 
epidermis130. In our material, there was no correlation between VGEF165b expression 
in primary melanomas or metastases and response to treatment with bevacizumab. 
Furthermore, there was neither a positive nor a negative correlation to VEGF-A 
expression in primary tumors or metastases (Paper II).  
VEGF-A expression in tumors is regulated by numerous growth factors, cytokines 
and HIF1-α126. HSP27 is another regulator of VEGF-A expression136 as described in 
chapter 1.7. Stressful conditions can result in HSP27 triggered degradation of a 
cytoplasmic protein complex that inhibits the transcription factor NF-κB292. As a 
consequence, NF-κB can be translocated to the nucleus and activates transcription of 
VEGF. Downregulation of HSP27 in an angiogenic breast cancer cell line resulted in 
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reduction of VEGF-A secretion and a non-angiogenic phenotype in vivo136. Based on 
these results, we wanted to investigate the role of HSP27 in our material. We found 
that strong expression of HSP27 in metastases was correlated to better objective 
response to treatment with bevacizumab monotherapy (Paper II). Still, HSP27 and 
VEGF-A expression in melanoma cells were not significantly correlated. It could be 
that this correlation would be positive with a larger samples size. Additionally, 
various factors are involved in angiogenesis and may be expressed at different levels 
at a certain time point293.  
Another important factor in angiogenesis is bFGF132. Like VEGF-A it is expressed in 
most melanoma cells but not by normal melanocytes279. Intratumoral bFGF 
expression in primary melanomas or metastases did not show any correlation to 
treatment response in our study (Paper II). Furthermore, there was no association of 
cytoplasmic bFGF expression and VEGF-A expression in our material. 
The proangiogenic role of IL1b and its interaction with VEGF-A and bFGF in vivo 
and in vitro is reviewed by Voronov et al.146. In our material, strong IL1b expression 
in metastases was correlated to strong expression of VEGF-A, bFGF and Activin A 
as well as a higher number of proliferating vessels (Paper III). Furthermore, patients 
with strong intratumoral expression of IL1b in metastases responded better to 
bevacizumab and had better PFS (Paper III). 
Patients with OR to bevacizumab showed also stronger Activin A expression in 
metastases than non-responders and we observed an association to the expression of 
other proangiogenic proteins and a higher number of proliferating vessels in 
metastases (Paper III). This is in line with findings from others who described a role 
of Activin A in expression of VEGF-A and bFGF as well as increased 
tubulogenesis148,149,294.  
5.2.3 Microvessel density  
Furthermore, we investigated the role of microvessel density (MVD) as a predictive 
marker for anti-angiogenic treatment. In addition, we also quantified the density of 
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proliferating vessels. Whole tissue sections were available for screening for F-VIII 
hot-spot areas258 in primary melanomas. These sections gave a more complete 
overview of hot-spot areas than smaller biopsies from metastases. Further, it is 
unknown from which part of the metastases the biopsies were taken. Intratumor 
heterogeneity results in varied metabolic and oxygenic conditions, and small needle 
biopsies can only capture a part of it. In addition, the material in some of the needle 
biopsies from metastases was sparse, so the number of proliferating vessels may be 
underrepresented in some of the samples. We observed significantly higher MVD in 
primary tumors of patients who responded to treatment with bevacizumab. However, 
MVD in metastases was not correlated to response (Paper II). Activated 
angiogenesis may characterize more aggressive primary tumors that metastasize, and 
clonal evolution may result in more angiogenic metastases. This is in line with the 
finding that high MVD in primary melanomas is an adverse prognostic factor176,275. 
The relevance of MVD as a predictive marker for anti-angiogenic treatment is still 
under discussion, since MVD is not necessarily a marker for angiogenic dependency 
of a tumor, and the grade of vascularization does not determine treatment response293. 
In our material, MVD or pMVD in metastases could not predict objective response 
(OR) to bevacizumab monotherapy. There are different advantages and weaknesses 
in determining MVD by the Weidner method295,296. Selection of the hot-spot area is 
done subjectively and markers defining the functional status of the endothelial cells 
are not included. Furthermore, there is no standardized method of MVD assessment, 
different endothelial cell markers have been used to determine MVD in various 
cancer types279,293,297 and there is no consensus whether MVD should be assessed in 
the periphery or the center of the tumor293. We co-registered MVD and pMVD to 
additionally investigate the role of proliferating vessels as predictive marker.  
Alternative angiogenesis independent mechanisms of vascularization may play a role 
in addition. Those vessels will not be detected by the markers we recorded and will 
possibly not be abolished by bevacizumab treatment. One mechanism is co-option of 
existing vessels as observed in gliomas and in well perfused organs like the brain, 
lung and the liver296,298 299. Another mechanism is vascular mimicry, i.e. tumor cells 
themselves form channels - without the participation of endothelial cells - to sustain 
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blood supply300. This controversial phenomenon is also described in highly invasive 
and aggressive melanomas301. McDonald et al. commented the findings by Maniotis 
critically302. They highlighted among others the importance of choosing established 
immunohistochemical markers to determine the presence and localization of 
endothelial cells and perivascular connective tissue correctly. Furthermore, they 
discussed the need to distinguish properly between intra- and extravascular 
erythrocytes and consecutively define the presence of a vessel lumen. Insufficient 
investigations may otherwise result in misinterpretation of findings. Nevertheless, the 
observation that tumor cells can contribute to vessel like structures has been reported 
by others previously302.     
5.2.4 Blood concentrations of various angiogenic factors 
The concentration of VEGF-A, HSP27, bFGF, uPAR and Activin A in blood samples 
was analyzed by ELISA, and in addition 60 factors involved in angiogenesis were 
assessed in a multiplex protein array. Serum samples were used for all analyses; 
VEGF-A concentration by ELISA was also measured in plasma samples.  
None of these angiogenic factors analyzed by ELISA could predict response to 
treatment with bevacizumab (Paper II, Paper III). These findings are in line with 
the results from others investigating the predictive value of VEGF-A and bFGF in 
melanoma patients242,263,303. Gringol et al. found no association between concentration 
of VEGF-A at baseline and response to treatment; contrary, low concentration of 
bFGF was associated with partial response304. Serum levels of HSP27 were increased 
in patients with hepatocellular carcinoma305, breast cancer306 and lung cancer307 
compared to healthy controls. However, HSP27 is not established as a predictive 
marker.  
Analyses by the multiplex protein array identified high concentration of Activin A as 
well as low concentrations of IL1b, uPAR and VEGF-A as potential predictive 
markers for treatment with bevacizumab (Paper III). Although, the concentrations of 
uPAR and VEGF-A measured by ELISA correlated to those measured by the 
multiplex array, the association to treatment response was only seen in the multiplex 
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array. These contradictory findings illustrate the challenges to identify robust 
predictive markers and may also be explained by technical issues (see 5.1.4).  
Furthermore, the serum concentrations of uPAR, IL1b, Activin A and VEGF-A were 
not correlated to the intratumoral expression of these proteins in metastases. Others 
also reported discrepancy between local and systemic concentrations of uPAR308, 
IL1b309 and VEGF-A310. IL1b is usually not detectable in serum samples of healthy 
subjects146 and has to be cleaved intracellularly before it is secreted in its active form. 
Differences in protein concentrations may also be explained by interactions between 
the tumor and its systemic environment.  
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6. CONCLUSIONS 
1) Treatment with bevacizumab monotherapy shows efficacy in patients with 
metastatic melanoma. We observed objective response in 6/35 (17%) patients 
and disease control in 11/31 (31%) of the patients (Paper I). 
 
2) Development of early hypertension is associated with response to treatment 
(Paper I). 
 
3) Response to treatment was not associated with BRAF or NRAS mutation status 
(Paper I). 
 
4) Strong expression of HSP27 protein in metastases is associated with response 
to treatment (Paper II). 
 
5) Microvessel density, the number of proliferating vessels or the presence of 
GMPs in metastases could not predict response to treatment (Paper II). 
 
6) Strong tissue expression of Activin A, IL1b and uPAR proteins in metastases 
was associated with response to treatment (Paper III). 
 
7) Candidate proteins could not be validated as predictive markers in serum 




7. FUTURE PERSPECTIVES 
Ongoing clinical trials focus mainly on immune check point blockade and targeted 
therapy for BRAF mutated melanomas as well as various combinations of these 
treatment options. Even tough, improvements in response rates, progression free 
survival and overall survival rates have been observed, many biological and 
mechanistic questions remain unanswered. Important issues are primary and acquired 
resistance, the role of the tumor microenvironment in progression and metastasis as 
well as the lack of reliable predictive biomarkers. Furthermore, only about 50% of the 
melanomas harbor BRAF mutations and not all patients are eligible for immune-
therapy. So, there is still a need to investigate further treatment options for these 
patients. We have shown that anti-angiogenic treatment may play a role in a 
subpopulation of melanoma patients and aim to further investigate the role of anti-
angiogenic treatment in a larger randomized clinical trial. In addition, the potential 
predictive markers we identified in our series have to be validated in a larger patient 
population. Thereby, validated predictive markers in blood samples would be 
preferable in clinical practice. 
Furthermore, we observed long lasting responses in a couple of patients beyond 
treatment with bevacizumab. Recent publications discuss the role of VEGF-A in the 
immune system. Treatment with a VEGF-A antibody may therefore contribute to a 
more anti-tumorigenic environment, and by this improve patient`s outcome. Clinical 
trials that combine anti-angiogenic and immune-modulating therapy in melanoma 
treatment are ongoing. We would like to further investigate VEGF-A as a predictor of 
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Abstract
Background: VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of
bevacizumab monotherapy in patients with metastatic melanoma.
Methods and Findings: Thirty-five patients with metastatic melanoma in progression were enrolled in this phase II, single
arm clinical trial. Each patient received bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease
progression occurred. Clinical efficacy was evaluated as objective response, disease control (DC), and survival. We observed
one complete (3%) and 5 partial (14%) responses. In addition, 5 patients experienced stable disease .6 months (14%) while
24 patients had progressive disease (PD, 69%), corresponding to a total DC at 6 months in 11 out of 35 patients (31%).
Median progression free survival (PFS) was 2.14 months and median overall survival (OS) was 9 months (1.12–49). Seven of
the 11 patients experiencing DC developed early hypertension (,2 months) compared to 3/24 of patients with PD
(P= 0.001), and hypertension was associated with PFS (P= 0.005) and OS (P= 0.013).
Conclusion: Bevacizumab monotherapy demonstrated promising clinical efficacy in patients with metastatic melanoma
with disease control in 31% of the patients. Induced early hypertension was a marker for clinical efficacy of bevacizumab.
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Introduction
Metastatic melanoma is a non-curable condition with limited
therapeutic options. Until recently, high dose interleukin-2 and
dacarbazine were the only regimens in routine use, with
response rates observed in about 10% of unselected pa-
tients[1–3]. While the human monoclonal anti CTLA-4
antibody ipilimumab was recently shown to cause a survival
benefit in stage IV melanoma [4], the drug was found active in
a fraction of patients only. Improved survival was also reported
for treatment of metastatic melanoma patients carrying a
specific BRAF mutation (,40% of all melanoma patients) using
the highly selective V600E kinase inhibitor vemurafenib [5].
Thus, while selected patients may benefit from novel treatment
options, effective treatment is still not available for a high
proportion of melanoma patients. In addition, patients benefit-
ting from conventional (interleukin-2 or dacarbazine) as well as
novel (ipilimumab and vemurafenib) therapeutic strategies
develop acquired therapy resistance over time, underlining the
need for alternative treatment options.
Melanoma progression and metastasis is dependent on angio-
genesis [6] and the vascular endothelial growth factor (VEGF)
system seems to be particularly important [7,8]. The humanized
monoclonal antibody bevacizumab is a highly specific inhibitor of
VEGF-A. Bevacizumab significantly prolonged overall survival
when given in combination with chemotherapy in colorectal
cancer [9] and in non-small cell lung cancer [10]. In addition,
responses have been reported in clinical trials evaluating
bevacizumab in combination with interferon alpha 2B [11],
interferon alpha 2A [12] or chemotherapy[13–15] in patients with
metastatic melanoma. Administered as monotherapy, bevacizu-
mab prolonged time to progression given in patients suffering from
metastatic kidney cancer [16].
To the best of our knowledge, no clinical trials have been
published specifically testing the clinical efficacy of bevacizumab
monotherapy in metastatic melanoma. Here, we report the results
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from a phase II trial evaluating clinical efficacy of bevacizumab
monotherapy in patients with metastatic melanomas.
Methods
Ethics
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and the International
Conference on Harmonization of Good Clinical Practice. The
protocol was approved by the Regional Ethics Committee and the
Norwegian Medicines Agency. All participating patients provided
signed informed consent before enrolment.
Patients
Between April 2005 and August 2009, 52 patients were
screened. Eligibility criteria included histologically confirmed
unresectable metastatic melanoma in progression; age .18 years;
WHO performance status 0–2; clinically and/or radiographically
measurable disease according to RECIST; .4 weeks since
adjuvant interferon; no prior interferon or interleukin for
metastatic disease; recovered from prior chemotherapy; no major
surgery within 28 days; no known brain metastases; absolute
neutrophils .1.06109/L; platelets .1006109/L; bilirubin, cre-
atinine, INR ,1.56upper normal limit; no symptomatic conges-
tive heart failure, angina pectoris, cardiac arrhythmia, history of
thrombosis, uncontrolled hypertension, full dose coumarin-derived
anticoagulants or NSAIDS.
Study Design
This was a phase II, open-label, single-arm, single institution
clinical trial (ClinicalTrials.gov Identifier: NCT00139360), per-
formed at the Haukeland University Hospital, Bergen Norway.
The full protocol is available online as supporting information
(Protocol S1). The primary objective was to determine clinical
efficacy, as measured by objective response (OR) and disease
control (DC) defined as stable disease (with or without an
objective tumor shrinkage) after 6 months on therapy.
Secondary objectives were to estimate time to progression
(TTP), progression free survival (PFS) and overall survival (OS).
Finally, we aimed at exploring potential relations between side
effects, including acquired hypertension as well as BRAF/NRAS
mutation status as potential predictive factors to clinical
response.
Initially, patients were included after confirmed progression on
standard first line treatment with dacarbazine (level A, n = 15).
Only after objective response was observed on bevacizumab
monotherapy, all new patients were subsequently enrolled for first
line treatment with bevacizumab (Level B, 20 patients) (Flow
diagram S1).
Each treatment cycle consisted of bevacizumab 10 mg/kg IV
on day 1 in a 2-weekly schedule. Thus, the chosen dose was higher
than the doses used in bevacizumab therapies for normalization of
tumor vasculature (5 mg/kg q14d) [17,18] and in line with the
dosing of bevacizumab monotherapy used in advanced renal
cancer where a survival benefit was indicated (10 mg/kg q14d)
[16]. Drug toxicity was assessed after each cycle, while the
response rate was evaluated after every 4 cycles. Patients with
disease progression or unmanageable toxicity were discontinued
and offered further melanoma treatment at the clinician’s
discretion. Standard clinical parameters (routine biochemistry,
urine analysis, blood pressure, WHO performance status) as well
as the mutational status for BRAF and NRAS were assessed for
subsequent correlation with clinical outcome.
Response Assessment and Toxicity
The primary endpoint was objective response (OR) defined as
complete response (CR) or partial response (PR) according to
RECIST [19] as well as disease control (DC) defined as CR + PR
and including stable disease (SD) for more than 6 months. Disease
stabilization is considered beneficial to patients experiencing
melanoma progression at the time of inclusion and DC is
frequently included as an additional statistical endpoint in trials
investigating new antiangiogenic drugs in which therapeutic
activity and clinical benefit are present, even in the absence of
radiological tumor shrinkage[20–22]. Importantly, all patients
were in clinical and/or radiological progression at the time of
inclusion. OR and DC were calculated on the basis of investigator
assessment. While confirmed response after 4 weeks was not a
protocol requirement, all patients achieving an objective response
had a subsequent confirmation at the next routine visit every 8
weeks. Patients with clinical disease progression or death due to
melanoma before first radiological progression were recorded as
progressive disease (PD), and best overall response (BOR) was not
available in these patients. TTP was defined as the time from
enrolment to disease progression or death due to melanoma.
Adverse events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse events,
version 3.0 [23], and were recorded by each 2-week cycle.
Tissue Sampling and DNA Analysis
To evaluate a possible relationship between the most frequent
genetic alterations in melanoma and treatment outcome, a
targeted mutational analysis was performed for BRAF and NRAS.
Tumor tissue was manually dissected from 3 paraffin sections
(10 mm) before extracting DNA with the E.Z.N.A Tissue DNA Kit
(Omega Bio-Tek, Inc., Norcross, GA, USA). BRAF exon 11 and
15, as well as NRAS exon 1 and 2 were amplified by PCR, and
screened for mutations by direct Sanger sequencing. Primers are
described elsewhere[24–26]. The sequence reactions were per-
formed using the Terminator Cycle Sequencing kit, BigDye
version 1.1 (Applied Biosystems, Foster City, CA, USA ), and were
analyzed on an ABI PRISMH 3100 Genetic Analyzer, applying
Sequencing Analysis software, version 3.7 (both from Applied
Biosystems).
Statistical Methods
The optimal two-stage design for phase II clinical trials
proposed by Simon [27] was used. The co-primary endpoint
DC was used to determine sample size. It was assumed that the
new regimen would have a DC rate of 30%. A DC rate of 10% or
lower was considered not superior to standard first-line therapy
(dacarbazine). With 10% type I error rate and 90% power a total
number of 35 patients were entered in the trial.
Two sample t-test and Mann-Whitney U test were used to
compare the distribution of continuous variables between two
groups such as responders and non-responders. Kaplan-Meier
estimates were constructed for time-to-event endpoints such as
PFS and OS, and log rank-test was applied for testing differences.
Due to the small sample size and the nature of the phase II study,
the above analyses were considered exploratory and the results
need to be confirmed in future large-scale studies.
Results
Patients
Between April 2005 and August 2009, 52 patients with
metastatic or unresectable melanoma in progression were screened
and 35 patients were enrolled in this trial. The seventeen screening
Bevacizumab Monotherapy in Malignant Melanoma
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failures were most frequently due to brain metastases, co
morbidity, or withdrawal of informed consent (Fig 1). During
recruitment at level A, 15 patients received bevacizumab as
second/third line treatment (after DTIC failure) while additional
20 more patients were included during recruitment level B (first
line therapy bevacizumab). Patient characteristics are listed in
Table 1.
Responses, PFS and Survival
In the study population of 35 patients, we observed 1 CR
(3%), 5 PR (14%), and 5 SD .6 months (14%). Thus, 24
patients (69%) progressed on therapy, including three patients
who progressed clinically before radiological tumor evaluation.
Best overall response (BOR), measured as the change in the
sum of largest diameter of the target lesions is illustrated in
Figure 2A. Duration of the responses in relation to patient
characteristics is illustrated in Figure 2B. Tumor responses were
observed at metastatic sites such as skin, lymph nodes, lung,
liver and ovaries (Fig 3).
At 6 months of follow up, 11/35 (31)% of the patients had no
sign of melanoma progression. This proportion was 8/20 for the
first line patients and 3/15 for the second/third line patients,
respectively. By August 2011, median PFS was 2.14 months
whereas mean PFS was 7.7 months (range 0.8–30 months), with a
median overall survival of 9 months (mean: 13, range: 1.1–49)
(Fig 4 A and B). The median number of cycles was 4 (mean: 14,
range: 1.0–64). No patients died of causes other than melanoma
progression. Six of the patients are still alive, and 5 of them are still
on bevacizumab treatment without signs of progression 15–30
months after starting bevacizumab.
Seven of 11 patients with DC developed early hypertension
(EH) as defined by CTCAEv3.0. In contrast, only three of 24
(12.5%) patients with progressive disease (PD) developed EH (Chi-
square test p,0.001). Median time to progression for patients who
developed EH following bevacizumab treatment was 11.4 months
Figure 1. Study flow diagram. Between April 2005 and August 2009, 52 patients with metastatic melanoma were screened. Thirty-five of those
patients were eligible according to inclusion criteria and received the study drug.
doi:10.1371/journal.pone.0038364.g001
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compared to 2.0 months in normotensive patients. EH was
significantly associated with prolonged PFS (log rank p= 0.001,
Fig 4C) as well as improved overall survival (log rank p= 0.005,
Fig 4D). To explore the possible association between the use of
different antihypertensive drugs and disease progression we
observed that 6 of 7 patients on concomitant beta blockers
experienced DC following treatment with bevacizumab mono-
therapy. In comparison, 3/6 patients who used antihypertensive
drugs other than beta blockers, or 2/22 who used no antihyper-
tensive drugs experienced DC (Chi square test p,0.001).
Stage M1a and b disease was significantly associated with DC
(7/7) as compared with M1c disease (4/28; Chi-square test
p,0.001). Similarly, 9 of 14 patients with normal levels of lactate
dehydrogenase (LDH) at baseline had DC as compared with 2 out
of 21 with increased LDH (Chi-square test p= 0.001). No
significant correlations were found between DC, OR, PFS or
OS and BRAF or NRAS mutation status, performance status, sex or
age.
Safety
Bevacizumab monotherapy, given as 10 mg/kg q14d IV was in
general well tolerated by the patients. No treatment related deaths
were recorded. Treatment was stopped in two patients with
CTCAE grade 4 toxicity (1 anaphylactic shock at cycle 2 and 1
lung embolus at cycle 5) and in one patient with grade 3
gastrointestinal toxicity (partial obstruction due to disease
progression at cycle 1). Treatment was interrupted in one patient
with grade 3 toxicity due to symptomatic left ventricular systolic
dysfunction after 16 cycles. All adverse events are listed in Table
S1 (online only). No dose reduction, interruption or postponement
due to fatigue or hypertension was necessary and no hemorrhage
was observed. Bevacizumab was delayed until proteinuria was
,2 g/24 h in three patients (,4 weeks), but no treatment was
stopped permanently due to proteinuria.
Hypertension according to CTCAEv3.0 was observed in 14
(40%) patients after initiation of bevacizumab. Grade 1:4 (11%),
grade 2:3 (9%) and grade 3:7 (20%), respectively. Median time to
induced hypertension was 43 days (mean: 59, range: 27–239). We
defined early hypertension (EH) as hypertension $ grade I
occurring before 1st tumor response evaluation at 8 weeks. EH was
recorded in 10 patients whereas 4 patients developed hypertension
at a later time point. As listed in Table 1, 8 (23%) of the patients
were treated for hypertension at the time of inclusion. Type of
antihypertensive drugs used is listed in Table S2.
Discussion
While some phase II studies have evaluated the use of
bevacizumab in concert with interferon alpha 2B [11,28],
interferon alpha 2A [12] or chemotherapy [13,14], to the best of
our knowledge this is the first study evaluating bevacizumab
monotherapy in metastatic malignant melanoma. Our results
provide a proof-of-principle that bevacizumab monotherapy is
active in metastatic melanoma with a disease control rate of 31%
and a 6 months PFS rate of 31%. In consistency with our finding,
a recently published study of the multi kinase inhibitor axitinib
(including VEGF receptor 1, 2 and 3) given as monotherapy
showed a OR rate of 18.8% and a DC rate of 37.5% in a similar
patient population [29]. These results are strikingly in line with
ours and are in support of a significant subgroup of melanoma
patients being susceptible to anti-VEGF strategies. Although not
meeting the primary objective of increased median progression
free survival, a recently published placebo controlled randomized
phase II study showed encouraging overall survival data in
metastatic melanoma patients treated with carboplatin and
paclitaxel 6 bevacizumab [15]. In contrast to our present
findings, the patients who benefitted most from that combination
were those with increased LDH and M1C disease, possibly
indicating different sensitivity between patients groups to combi-
nation therapy and monotherapy.
In metastatic melanoma new treatment options have recently
emerged targeting BRAF [5] or CTLA-4 [4] showing improved
overall survival, but these treatments are associated with significant
toxicities and costs. In addition, for BRAF negative patients or
patients with non-immunogenic disease only limited effective
treatment options are available. Significantly, in our study there
Table 1. Baseline Demographic and Clinical Characteristics of
Patients.




Sex - No. (%)
Male 19 (54)
Female 16 (46)




LDH.ULN - No. (%)
No 14 (40)
Yes 21 (60)
WHO performance status - No. (%)
0 28 (80)
1 7 (20)




Hypertension before treatment - No. (%)
No 27 (77)
Yes 8 (23)
BRAF exon 15 mutation – No. (%)
Wild type 20 (57)
V600E 13 (37)
V600K 1 (3)
V600D/V600E Double mutation 1 (3)
NRAS exon 2 mutation - No. (%)





Not amplifiable 1 (3)
Abbreviations: LDH, lactate dehydrogenase; ULN, upper limit of normal; WHO,
World Health Organization.
doi:10.1371/journal.pone.0038364.t001
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Figure 2. Patterns of response to treatment with bevacizumab monotherapy in metastatic malignant melanoma patients. Panel A
shows the best overall response for 32 patients who had undergone at least one tumor assessment measured as the change from baseline in the sum
of the largest diameters of each target lesion. Three patients progressed clinically and/or biochemically before first tumor assessment, and are not
shown. Negative values indicate tumor shrinkage, and the dashed lines indicate the threshold for a partial response (PR) and progressive disease (PD),
respectively. Panel B shows the duration and characteristics of the responses in each patient.
doi:10.1371/journal.pone.0038364.g002
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was a subset of patients (14%) showing long-term survival on
treatment (.2 years), independent of BRAF or NRAS mutational
status.
Predictive markers for response to antiangiogenic treatment
are urgently needed to guide clinical decision making and to
target therapy towards well selected subgroups of patients. The
present lack of useful predictive biomarkers decrease the
likelihood of benefits, cost-effectiveness and therapeutic out-
comes [14,30]. We provide evidence that the clinical benefit of
bevacizumab monotherapy in metastatic melanoma is almost
exclusively limited to those patients who develop early
hypertension during treatment. This can in part be explained
by the fact that some non-responders did not have sufficient
time on bevacizumab to develop hypertension. Still, most of the
hypertensive patients (10/14) were recorded with hypertension
before the 1st tumor evaluation in week 8 (early hypertension).
This phenomenon has been reported for several antiangiogenic
drugs [30], and early onset hypertension is one of few markers
at the present have been found to predict response to
antiangiogenic drugs [30,31].
The causal mechanism behind induced hypertension by
antiangiogenic drugs is still elusive. VEGF upregulates nitric
oxide [32] and prostacyclin [33], leading to vasodilatation,
which is counteracted by bevacizumab. Also, the secondary
hypotension following vascular permeability and leakiness
caused by VEGF is counteracted by VEGF inhibition [34].
Figure 3. Computed tomography showing partial responses in three different patients at baseline and at 12 months. Panel A shows
ovarian metastases in a 43 years old woman. Panel B shows lung metastases in a 50 years old man. Panel C shows liver metastases and pleural
effusion (*) in a 70 years old man. Arrows show the largest diameter of the lesions.
doi:10.1371/journal.pone.0038364.g003
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The angiogenic effect of players in the sympathetic nervous
system associated with hypertension like norepinephrine (NE),
has been reported [35]. Induction of VEGF and HIF-1a
expression by NE was completely abolished by the beta blocker
propranolol [36], suggesting a possible dual inhibition of VEGF
when beta blockers are given together with bevacizumab.
Clinical impact of beta blockers in cancer patients has been the
focus of several large clinical and epidemiological studies, and
these drugs can significantly reduce cancer progression and
mortality [37–40], and might represent a promising drug
combination with bevacizumab. Interestingly therefore, we
found beta blocker use together with bevacizumab to be
significantly associated with disease control. Still, this trial was
not designed to analyze beta blocker use independently from
hypertension, and the data must be interpreted with caution.
[41]
In conclusion, bevacizumab monotherapy yielded promising
data regarding disease control, progression free survival and
overall survival in patients with metastatic melanoma, and the
responders were typically characterized by induced hypertension
early during therapy.
Figure 4. Kaplan Meyer plots of progression free survival (PFS) (A) and overall survival (OS) (B) in 35 metastatic melanoma patients
treated with bevacizumab monotherapy. Early hypertension (EH) was significantly associated with PFS (C) and OS (D).
doi:10.1371/journal.pone.0038364.g004
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Supplemental Table S1
Table S1. Drug related toxicities of bevacizumab 10mg/kg q2w for metastatic 
melanoma (n=35). NCI CTCAE v3.0*.
All grades Grade 1 Grade 2 Grade 3 Grade 4
Adverse effect No. % No. % No. % No. % No. %
Fatigue 5 14 3 9 2 6
Proteinuria 12 34 9 26 3 9
Pain 3 9 3 9
Ileus 1 3 1 3
Left ventricular
systolic dysfunction
1 3 1 3
Allergy 1 3 1 3
Nausea 2 6 2 6
Lung embolus 1 3 1 3
Hypertension 14 40 4 11 3 9 7 20
* National Cancer Institute Common Terminology Criteria for Adverse Events v.3.0.
Supplemental Table S2
Table S2. Antihypertensive drugs used during treatment in 35 patients
Drug type No. %
-selective beta blockers 5 14
Non-selective beta blockers 2 6
ACE* inhibitors 2 6
AT II** antagonists 8 23
Calcium antagonists 7 20
Diuretics 7 20
No antihypertensive drugs 22 62
Combinations with beta blockers 5 14
Combinations without beta blockers 6 17
Beta blockers *** without combination 2 6
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Abstract
The aim of this study was to identify potential predictive biomarkers in 35 patients with meta-
static melanoma treated with anti-angiogenic bevacizumab monotherapy in a clinical phase
II study. The immunohistochemical expression of various angiogenic factors in tissues from
primary melanomas and metastases as well as their concentration in blood samples were
examined. Strong expression of Heat Shock Protein 27 (HSP27) in metastases correlated
significantly with complete or partial response to bevacizumab (p = 0.044). Furthermore,
clinical benefit, i.e., complete or partial response or stable disease for at least 6 months,
was more frequent in patients with strong expression of HSP27 in primary tumors (p =
0.046). Tissue expression of vascular endothelial growth factor (VEGF-A), its splicing vari-
ant VEGF165b or basic fibroblast growth factor (bFGF) did not correlate with response, and
the concentration of HSP27, VEGF-A or bFGFmeasured in blood samples before treatment
did not show predictive value. Further, microvessel density, proliferating microvessel den-
sity and presence of glomeruloid microvascular proliferations were assessed in sections of
primary tumors and metastases. Microvessel density in primary melanomas was signifi-
cantly higher in patients with clinical benefit than in non-responders (p = 0.042). In conclu-
sion, our findings suggest that strong HSP27 expression in melanoma metastases predicts
response to bevacizumab treatment.
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Introduction
Cutaneous malignant melanoma (CMM) has shown an increasing incidence worldwide among
fair skinned populations during the last decades [1]. Five-year survival in metastatic disease is
still poor [2], and it remains to be seen whether new options like targeted treatment [3] or
immune checkpoint blockade [4] will improve long term survival rates. Acquired resistance [5]
and initial low response rates [6] are still major reasons for poor outcome, and predictive bio-
markers in addition to BRAFmutation status are needed [3].
Angiogenesis is an important cancer hallmark and treatment target [7, 8]. Preclinical mod-
els and clinical investigations have characterized primary melanomas and metastases as highly
vascularized [9–11]. Since vascular endothelial growth factor A (VEGF-A) plays a key role in
angiogenesis [12, 13] and is expressed in a high proportion of melanomas [9], we conducted a
clinical trial with bevacizumab monotherapy, a humanized monoclonal antibody that binds
specifically to VEGF-A, in patients with metastatic CMM [14]. As published previously, we
observed a clinical benefit rate of 31% [14], indicating that VEGF-A driven angiogenesis is
important in a subgroup of these patients. In addition, efficacy of different combinations
between bevacizumab and chemotherapy in patients with metastatic melanoma has been
reported [15–18]. Bevacizumab is also implemented in the treatment of various other solid
tumors but still no predictive biomarkers have been validated [19, 20].
In the present study, we aimed to explore potential predictive biomarkers known to be
involved in angiogenesis, and we focused on VEGF-A [12, 13], its splicing variant VEGF165b
that binds competitively to VEGFR-2 without phosphorylating pro-angiogenic pathways [21],
basic fibroblast growth factor (bFGF) [8] and Heat Shock Protein 27 (HSP27).
HSP27, a small heat shock protein, maintains cell survival under stressful conditions by
management of misfolded proteins and prevention of apoptosis [22, 23]. Furthermore, it
appears to play an important role in angiogenesis and in tumor cell migration as well as in
organization of the cytoskeleton [23, 24]. HSP27 expression is associated with impaired prog-
nosis in melanoma and other tumors as well as resistance to chemotherapy [23, 24]. Previous
studies from our group have identified HSP27 as important for tumor dormancy, angiogenesis
regulation and tumor progress in cutaneous melanoma and breast cancer [24]. Downregula-
tion of HSP27 in an angiogenic breast cancer cell line resulted in reduced secretion of VEGF-A
and bFGF, supporting a HSP27 dependent co-regulation of these factors. Furthermore, the
expression of HSP27-related transcription factors phospho-STAT3 and NFkB, involved in reg-
ulation of angiogenesis, were significantly reduced in xenograft tumors from HSP27 knock-
down cells [24]. Others showed increased secretion of VEGF after endothelial cells were
exposed to extracellular HSP27 [25].
Importantly, tissue based angiogenesis markers like microvessel density (MVD), proliferat-
ing microvessel density (pMVD), vascular proliferation index (VPI) and presence of glomeru-
loid microvascular proliferation (GMP) [11, 26–28] were studied. To our knowledge, the
present study is the first to indicate that strong tissue expression of HSP27 in melanoma metas-
tases predicts overall response to treatment with bevacizumab monotherapy. However, several
other angiogenic markers were not predictive in our study.
Material and Methods
Patients and study design
Thirty-five patients with metastatic melanoma were enrolled in an open-label, single arm phase
II study at Haukeland University Hospital, Norway, and were treated with bevacizumab 10 mg/
kg q14d until disease progression or intolerable toxicity (ClinicalTrials.gov: NCT00139360).
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Study design, eligibility criteria and clinical response data were reported earlier [14]. Fourteen of
the thirty-five patients were treated with dacarbazine before they were included in the study.
One of these patients received bevacizumab as third line treatment. Twenty-one patients were
treated with bevacizumab first line. This approach was based on the two-stage design for phase
II clinical trials by Simon [29]. As published previously [14], six of the thirty-five patients had
an overall response (OR), i.e. complete (CR) or partial response (PR), following treatment with
bevacizumab monotherapy. In addition, five more patients had stable disease (SD) for at least
six months. Thus, altogether 31% had a clinical benefit (CB), i.e. OR and SD. The study was con-
ducted in accordance with the ethical principles of the Declaration of Helsinki and the Interna-
tional Conference on Harmonization of Good Clinical Practice, and approved by the Regional
Ethics Committee (processing number: 05/329) and the Norwegian Medicines Agency.
Informed consent was signed by all patients before enrolment.
Tissue and blood samples
Paraffin embedded tissue of primary tumors was obtainable in 32 of 35 patients. The three
cases missing primary tumor tissue blocks represent one primary ocular melanoma treated by
radiation therapy, one unknown primary lesion, as well as one undiscoverable tissue block. All
primary melanomas were reclassified (LAA, CS) and characterized by the following histopath-
ologic features in hematoxylin and eosin-stained sections: histologic type by Clark, tumor
thickness by Breslow, mitotic rate, ulceration, Clark’s level of invasion, growth phase, vascular
invasion, tumor infiltrating lymphocytes and necrosis [30].
Tissue samples from metastases were available in all patients (35/35). The metastasis diag-
nosed closest to the date of inclusion (median 5 days) was chosen for further analysis if several
metastatic lesions were available. The material includes core needle biopsies (n = 17), mostly
taken from lung, liver and abdominal or pelvic organs, as well as excisional biopsies (n = 18)
from skin metastases or lymph nodes.
In addition, plasma and serum samples were taken before the first treatment with bevacizu-
mab (median: 2 days); altogether 29 plasma and 28 serum samples were available. EDTA blood
was immediately centrifuged at +4°C for 10 minutes at 1600xg, serum samples were processed
after clotting for 30 minutes at room temperature. All samples were stored at -20°C and ali-
quoted when used for analysis.
Immunohistochemistry
Tissue sections of 4–5 μmwere stained with primary antibodies for HSP27, VEGF-A, VEGF165b
and bFGF. Furthermore, double staining with anti-factor VIII (F-VIII) and Ki67 was performed
for angiogenesis assessment. After deparaffinizing in Xylene and different alcohol dilutions and
rehydration, heat mediated or enzymatic antigen retrieval was performed. Endogenous peroxi-
dase and alkaline phosphatase were blocked before incubation with the primary antibody fol-
lowed by incubation with appropriate HRP-EnVision (DAKO, K4011 or K4007). For staining
with HSP27 a secondary rabbit anti-goat antibody (Southern Biotech, Cat. no. 6164–01) was
used; for double staining, a secondary goat anti-mouse antibody (Southern Biotech, Cat. no.
1031–04) was used. Details are provided in Table 1. For negative controls, primary antibodies
were omitted or specific blocking peptides for HSP27, VEGF-A and bFGF were added. Tissues
from different cancer types were used as positive controls.
Evaluation of tissue staining results
Evaluation of HSP27, VEGF-A, VEGF165b and bFGF expression. All sections were sub-
jectively screened in a light microscope (Olympus CX31) at magnifications x40 and x100 to
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determine areas containing at least 50% tumor tissue; areas of ulceration or necrosis within the
tumor were avoided. Subsequently, staining intensity and the proportion of positive tumor
cells and endothelial cells (ECs) within the area of each high power field (HPF, x400) were
recorded using a semi-quantitative grading. Staining intensity was defined as absent (0), weak
(1), moderate (2) or strong (3). The proportion was rated as “no positive tumor cells” (0), “less
than 10% positive tumor cells” (1), “10–50% positive tumor cells” (2) or “more than 50% posi-
tive tumor cells” (3). The staining index (SI) is the product of intensity and area (range 0–9)
[9]; SI was used to determine cytoplasmic staining of VEGF-A and HSP27 and to record cyto-
plasmic and nuclear staining of VEGF165b and bFGF. The SI was evaluated by two observers
(CS, OS) blinded for response data.
Evaluation of microvessel density and glomeruloid microvascular
proliferations
Assessment of MVD and pMVD was done after dual staining (F-VIII/Ki67). F-VIII positive
ECs and microvessels were counted in three HPFs to assess MVD in primary tumors and
metastases. Sections were first screened at lower magnification (x40 and x100) for selection of
MVD hot-spot areas defined by high intensity of F-VIII [11, 26]. Areas of ulceration or necro-
sis within the tumor were avoided. Microvessels with co-expression of Ki67 in the nucleus and
F-VIII in the cytoplasm of ECs were defined as proliferating vessels. The pMVD was recorded
in the same three HPFs chosen for assessment of MVD. Ki67 positive nuclei within the lumen
or outside ECs were excluded. Both MVD and pMVD were reported as microvessel per mm2.
In addition, VPI was calculated as the ratio between pMVD and MVD (% of 100) [27].
Assessment of GMP was done after staining with F-VIII and hematoxylin counterstain.
GMPs were defined as the presence of focal glomerulus-like aggregates of related multilayered
F-VIII positive ECs with a minimum number of 15 cells. After screening the tumor at lower
magnification, GMPs were registered by x100 magnification in a maximum of four consecutive
HPFs within the area of highest density. Presence or absence of GMPs was finally reported
[28].
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed according to the manufacturer`s instructions for HSP27 (Enzo Life Sci-
ence, ADI-EKS-500) and for bFGF (R&D systems, DFB50) in serum samples as well as for
Table 1. Immunohistochemical stainingmethods.
Antibody Provider Epitope retrieval Dilution Incubation
HSP27 pAb sc-1048 (goat) Santa
Cruz
MW 6th sense 20 min,
pH6
1:100 30 min, RT
VEGF-A pAb sc-152 (rabbit) Santa
Cruz
MW 6th sense 20 min,
pH9
1:50 60 min, RT




FGF-2 pAb sc-1390 (rabbit) Santa
Cruz
Pressure cooker, pH9 1:50 60 min, RT
Von Willebrand Factor pAb A0082 (rabbit) Dako Proteinase K, 5 min 1:800 30 min, RT
Von Willebrand Factor pAb A0082 (rabbit) and Ki67 mAb (mouse)
M7240





pAb, polyclonal antibody; MW, microwave; RT, room temperature; mAb, monoclonal antibody.
doi:10.1371/journal.pone.0155242.t001
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VEGF-A165 (R&D systems, DVE00) in plasma and serum samples. Some samples were diluted
to fit within the absorbance of the HSP27-standard curve. Samples were run in duplicates.
Referring to the user`s manual, the MDD was less than 0.39 ng/ml for HSP27, 3.0 pg/ml for
bFGF and 9.0 pg/ml for VEGF. Results below these limits were considered to be zero.
Statistics
Statistical analyses were performed with SPSS, version 22 (SPSS Inc., Chicago, IL). For compar-
ison of two categorical variables, Pearson`s chi-square test was used. Since not all data followed
normal distribution, non-parametric tests were used for all analyses. Continuous and ordinal
variables were assessed by the Mann-Whitney U Test (MWT) or the Kruskal-Wallis Test
(KWT). Intratumoral protein expression, MVD or pMVD in primary tumors and metastases
as well as blood concentrations were independent variables when MWT was performed to cal-
culate the association with response or treatment line. Kruskal-Wallis test was used to calculate
the association between Breslow thickness and protein expression in primary melanomas
(independent variable). The association of various proteins and angiogenic factors between pri-
mary tumors and metastases were calculated by the paired Wilcoxon Test (pWT) by the
assumption that samples from the primary melanoma and the metastasis are matched pairs.
Strength and direction of correlations between two interval scaled continuous or ordinal vari-
ables or one of each type were calculated by Spearman`s rho correlation. The level of signifi-
cance was defined as p< 0.05. When continuous variables were categorized, the median was
used as cut-point if no other cut-point is defined. The statistical analyses of this study were per-
formed with pre-specified hypotheses for a limited number of intratumoral proteins related to
VEGF-A associated angiogenesis. Thus, we did not correct for multiple testing.
Results
Tissue expression of angiogenic factors
HSP27. HSP27 was expressed in the cytoplasm of melanoma cells in all primary tumors
and metastases. The median staining index (SI) was 6 for both primary tumors and metastases
(p = 0.74; paired Wilcoxon Test, (pWT)). Strong HSP27 expression in metastases was signifi-
cantly associated with overall response (OR) to treatment with bevacizumab monotherapy.
Median HSP27 SI for patients with OR was 7.5 compared to a median SI of 6 in patients with
stable disease (SD) or progressive disease (PD) (p = 0.044; Mann-Whitney U Test (MWT); Fig
1A and 1B; Table 2). Although some patients with HSP27 overexpression did not respond to
treatment, no one with low or absent HSP27 expression belonged to the OR-group. There
was also a trend for an association between HSP27 expression and OR in primary tumors
(p = 0.097; MWT), and HSP27 staining in primary melanomas was significantly associated
with CB from bevacizumab treatment (p = 0.046; MWT, S1 Table). Histologic features of the
primary tumors were not associated with HSP27 expression, nor with response. Median
HSP27 staining in metastases was significantly stronger within the group treated in first line
with bevacizumab compared to second line treatment (median SI 6 vs 3, p = 0.008; MWT, S2
Table).
VEGF-A. Cytoplasmic expression of VEGF-A was assessed separately in melanoma cells
and ECs in primary tumors and metastases. All primary melanomas, except one, expressed
VEGF-A in tumor cells (median SI = 5), and most metastases as well (33 of 35; median SI = 4).
However, the difference in VEGF-A SI between primary tumors and metastases was not signifi-
cant (p = 0.71; pWT). VEGF-A expression in metastases was neither significantly correlated to
OR (Fig 2A and 2B) nor to CB (Table 3). Treatment outcome did not depend on VEGF-A
expression in primary tumors (S3 Table). VEGF-A expression in metastases did not correlate
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significantly with HSP27 expression in metastases. VEGF-A expression in primary tumors was
not associated with any of the histologic features. Median VEGF-A expression was significantly
stronger in metastases from patients treated with bevacizumab in first line compared to
patients treated in second line (median SI 6 vs 3 p = 0.016; MWT, S4 Table).
VEGF-A expression in tumor associated ECs was present in 21/32 (66%) of primary tumors
and 15/35 (43%) of metastases. There was no association between EC-VEGF-A expression
(primary melanoma or metastases) and response to treatment.
VEGF165b. Both cytoplasmic and nuclear expression of VEGF165b was observed in
tumor cells of all primary melanomas and metastases. The median cytoplasmic SI was similar
in primary tumors and metastases (p = 0.22; pWT) but the nuclear SI was significantly lower in
metastases (p = 0.045; pWT, S1 Fig). The expression level of VEGF165b in primary tumors or
metastases was not associated with response to treatment. No associations with histologic fea-
tures or expression of VEGF-A were observed.
Fig 1. HSP27 expression in metastases predicts overall response to treatment with bevacizumab. (A)
HSP27 expression in metastases grouped by treatment response. CR: complete clinical response, PR:
partial response, SD: stable disease, PD: progressive disease. (B) Examples for low, moderate and high
staining index for HSP27. Original magnification x630.
doi:10.1371/journal.pone.0155242.g001
Table 2. Descriptive data for HSP27 expression in metastases.
HSP27 expression in metastases Overall response (OR) No OR Clinical benefit (CB) No CB
Mean SIa +/-SEMb 7.2 +/- 0.9 5.0 +/- 0.4 6.3 +/- 0.8 4.9 +/- 0.4
Median SI* 7.5 6 6 5
Minimum SI 4 2 2 2
Maximum SI 9 9 9 9
Number of patients 6 29 11 24
* p = 0.044 (OR), p = 0.15 (CB);
Mann-Whitney U Test.
a: Staining index (SI);
b: Standard error of mean (SEM).
doi:10.1371/journal.pone.0155242.t002
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bFGF. Cytoplasmic bFGF expression was observed in 31/32 primary melanomas and all
metastases; nuclear bFGF expression was seen in 30/32 primary melanomas and 28/35 metas-
tases. The median nuclear SI was similar in primary tumors and metastases (p = 0.174; pWT)
but the cytoplasmic SI was significantly lower in metastases (p = 0.030; pWT, S2 Fig). There
was no association between expression of bFGF in primary melanomas or metastases and
response to treatment. Regarding histologic features, primary tumors with a mitotic rate< 1/
mm2 showed stronger cytoplasmic and nuclear expression of bFGF (p = 0.03 and p = 0.02;
MWT), and strong nuclear expression was associated with the absence of ulceration and lower
Breslow thickness (p = 0.014; MWT; p = 0.021; Kruskal-Wallis test (KWT)).
MVD, pMVD, VPI and GMP. Quantification of angiogenesis markers MVD, pMVD and
GMP was based on immunohistochemical staining of tumor associated ECs and proliferating
ECs. Median MVD was 89/mm2 (mean 90/mm2) in primary melanomas and 108/mm2 (mean
107/mm2) in metastases; thus, MVD was significantly higher in metastases than in primary
Fig 2. VEGF-A expression in metastases is not associated with overall response to bevacizumab. (A)
VEGF-A expression in metastases grouped by treatment response. CR: complete clinical response, PR:
partial response, SD: stable disease, PD: progressive disease. (B) Examples for low, moderate and high
staining index for VEGF-A. Original magnification x630.
doi:10.1371/journal.pone.0155242.g002
Table 3. Descriptive data for VEGF-A expression in metastases.
VEGF-A expression in metastases Overall response (OR) No OR Clinical benefit (CB) No CB
Mean SIa +/- SEMb 5.7 +/- 1.1 4.3 +/- 0.5 5.4 +/- 0.8 4.2 +/- 0.6
Median SI* 5 3 6 3
Minimum SI 3 0 2 0
Maximum SI 9 9 9 9
Number of patients 6 29 11 24
a: Staining index (SI);
b: Standard error of mean (SEM)
* p = 0.27 (OR), p = 0.30 (CB);
Mann-Whitney U Test.
doi:10.1371/journal.pone.0155242.t003
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melanomas (p = 0.031; pWT). High MVD in primary tumors predicted CB to treatment with
a median MVD of 103/mm2 in responders vs. 83/mm2 in non-responders respectively
(p = 0.042; MWT), (Fig 3A and 3B; S3 Fig). No significant association was present between
MVD in metastases and treatment response. However, high MVD in metastases was correlated
to strong VEGF-A expression (p = 0.025; r = 0.39; Spearman).
Median pMVD was significant lower in primary melanomas (3.6/mm2; mean 5.8/mm2)
than in metastases (8.9/mm2; mean 9.9/mm2) (p = 0.01; pWT). There was no association
between pMVD and treatment response. Also, median VPI was significantly lower in primary
melanomas (5.1; mean 6.1) than in metastases (7.8; mean 10.4) (p = 0.035; pWT). VPI was not
associated with treatment response. In primary tumors, strong VEGF-A expression was corre-
lated to higher levels of pMVD and VPI (p = 0.028 and p = 0.027; r = 0.39 for both; Spearman).
GMPs were present in 8/32 (25%) of primary melanomas and 4/34 (12%) of metastases.
Presence of GMPs (primary melanomas or metastases) did not predict response to treatment.
Concentrations of angiogenic factors in blood samples
HSP27 concentration in serum samples. All measurements of HSP27 concentration in
serum (sHSP27) were above minimal detectable dose (MDD) (median 7.07 ng/ml). sHSP27
concentration was not associated with response to treatment (S11 Table). Notably, there was
no association between sHSP27 concentration and tissue expression of HSP27 in metastases,
nor with VEGF-A tissue expression. High sHSP27 was correlated with high VEGF-A in plasma
and serum as well as with high bFGF in serum (p = 0.004; r = 0.52; p = 0.038; r = 0.39 and
p<0.001; r = 0.76; Spearman, respectively). Notably, median sHSP27 was nine fold higher in
patients treated with bevacizumab in second line compared with first line (p<0.001; MWT,
S12 Table). Further, high sHSP27 was related to high LDH at the time of inclusion (p = 0.039;
r = 0.39; Spearman). sHSP27 was not correlated to MVD, pMVD, VPI or GMP in metastases.
VEGF-A concentration in serum and plasma samples. The VEGF-A concentration was
above MDD in all serum samples (sVEGF, median 345 pg/ml) and in 23/29 plasma samples
(pVEGF, median 52 pg/ml). High VEGF-A concentration in serum was significantly correlated
to high VEGF-A concentration in plasma (p<0.001; r = 0.75; Spearman). VEGF concentrations
in serum or plasma were not associated with response to treatment (S11 Table). Furthermore,
there was no correlation to VEGF-A expression in metastases. Median pVEGF was almost
six fold higher in patients treated with bevacizumab in second line compared with first line
(p = 0.017; MWT, S12 Table). High sVEGF and pVEGF were associated with high bFGF
in serum (p = 0.029; r = 0.41 and p = 0.004; r = 0.52; Spearman) and high baseline LDH
(p = 0.018 and p = 0.032; r = 0.4; for both, Spearman). There were no significant correlations
between VEGF concentrations in blood samples and tissue based angiogenesis markers (MVD,
pMVD, VPI, GMP) in metastases.
bFGF in serum. The bFGF concentration in serum (s-bFGF) was above MDD in 21/28
samples (median 7.8 pg/ml). The concentration of bFGF was not associated with response to
treatment (S11 Table). High s-bFGF was correlated to high sHSP27 and high plasma and
serum VEGF (see above). bFGF concentration in serum was not associated with expression
of any tissue markers in metastases including MVD, pMVD, VPI or GMP status. Notably,
median bFGF was significantly higher in serum samples from patients treated in second line
(p = 0.002; MWT, S12 Table).
Discussion
Several attempts to identify biomarkers of response to bevacizumab or other anti-angiogenic
drugs were recently reviewed by Lambrechts et al. [19]. Validation of potential predictive
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biomarkers for anti-angiogenic treatment is important to avoid severe side-effects among
patients without benefit, and to define treatment indications for optimized and personalized
medicine. Since angiogenesis is a complex and dynamic process involving many different
growth factors, cytokines and interactions with the stroma [31], there is a challenge to identify
individual predictive markers.
Multiple angiogenic factors have been investigated in randomized trials for various cancers
[19]. Still, none are currently established as predictive markers. The role of VEGF-A and differ-
ent VEGF-A SNPs as response predictors has been investigated in clinical trials of bevacizu-
mab. The results are inconsistent, and although associations to improved progression free [32]
or overall survival [33] were reported in some trials, none of these markers have been firmly
validated [19, 34].
So far, treatment induced hypertension appears to predict clinical benefit in patients treated
with anti-angiogenic drugs as reported in metastatic renal cell cancer [35] and metastatic mela-
noma [14]. In contrast, early hypertension did not predict treatment response in metastatic
colorectal cancer when bevacizumab was given in combination with chemotherapy [36].
Here, as a novel finding, strong tissue expression of HSP27 in melanoma metastases was
associated with overall response (OR) to bevacizumab monotherapy. Strong expression of
HSP27 in metastases characterized all patients with OR, and no patients with weak or absent
HSP27 expression were among the responders. Other studies have identified strong HSP27
expression as a prognostic marker for poor outcome in various solid tumors [37–39], and
increased intratumoral expression is associated with more advanced tumor stages in ovarian
cancer [40]. Furthermore, strong HSP27 expression in vitro and in vivo is associated with resis-
tance to chemotherapy and its downregulation increased sensitivity to treatment [40–43].
HSP27, which is phosphorylated and activated in cells under stressful conditions like hypoxia,
is involved in angiogenesis by regulating expression and secretion of VEGF as previously
reported [24, 25]. Straume et al. investigated the mechanistic role of HSP27 in angiogenesis in
Fig 3. Highmicrovessel density (MVD) in primary tumors predicts clinical benefit to treatment with
bevacizumab. (A) MVD in primary melanomas grouped by treatment response. Median MVD in primary
melanomas is significantly higher in patients with clinical benefit. CR: complete clinical response, PR: partial
response, SD: stable disease, PD: progressive disease (B) Immunohistochemical staining showing high and
low MVD. Original magnification x100.
doi:10.1371/journal.pone.0155242.g003
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various models. Knockdown of HSP27 in an angiogenic breast cancer cell line resulted in phe-
notypic non-angiogenic and microscopic xenograft tumors. Gene expression analysis showed
reduced expression of HSP27 as well as of VEGF-A and bFGF [24]. In addition, strong expres-
sion of HSP27 was associated with decreased survival in melanoma and breast cancer [24]. Our
present finding that strong expression of HSP27 in melanoma metastases is associated with
response to anti-VEGF therapy, is in support of HSP27 being a negative prognostic factor and
a predictive indicator for treatment response. The reason for this might be that increased
HSP27 expression identifies an aggressive melanoma phenotype with an active VEGF depen-
dent angiogenesis that is more sensitive to anti-VEGF treatment.
Although we found a strong correlation between sHSP27 and pVEGF, sVEGF as well as s-
bFGF in blood samples taken before treatment with bevacizumab, there was no association
between tissue expression of HSP27 in metastases and sHSP27, similar to a previous study on
breast cancer [44], and no relationship between blood levels of these factors and response to
treatment.
Apart from the significant correlation between high MVD in primary tumors and clinical
benefit, we observed no significant associations between VEGF, bFGF (in tissues or blood sam-
ples), VEGF165b or tissue based angiogenesis markers and response to treatment. This is in
line with the disappointing conclusions from multiple studies of anti-angiogenesis treatment
and biomarkers in various cancers [19, 34, 45].
The associations of all assessed intratumoral proteins and angiogenic factors between the
primary tumors and metastases were investigated. The median protein expression was similar
in primary tumors and metastases except for cytoplasmic bFGF and nuclear VEGF165b. Con-
trary, the median of MVD, pMVD and VPI was significantly higher in metastases. Based on
these findings, a biopsy of the metastatic lesion should be used for investigations of predictive
factors.
There was a lack of consistent associations between tissue expression of angiogenesis mark-
ers and their levels observed in plasma or serum samples. These findings might be explained by
changing tumor-stroma interactions and heterogeneity in primary tumors and metastases, as
well as the possibility of clonal evolution and tumor progression in metastatic tumors. Under
physiologic angiogenesis, i.e. during wound healing, an inverse relation between local and sys-
temic levels of angiogenic factors has been repeatedly observed [46, 47]. These changes might
in part explain the challenges in robust quantification of dynamic growth factors, especially
ligands like VEGF and bFGF, during cancer progression and treatment.
Since VEGF-A is a key player in angiogenesis and a specific treatment target on this trial, we
also looked at associations between VEGF-A and other markers. VEGF-A tissue expression
was significantly associated with microvessel proliferation (pMVD and VPI) in primary mela-
nomas, and with overall microvessel density (MVD) in metastases. Taken together, our find-
ings support an important role of VEGF-A in melanoma angiogenesis and progression as
previously indicated [28]. Nevertheless, none of these angiogenesis markers were associated
with blood levels of VEGF. Our results are in line with findings by Byrne et al. who reported
that VEGF expression in primary breast cancer patients was significantly associated with MVD
but not with VEGF concentration in platelet-depleted plasma [48].
The intratumoral expression of some proteins as well as their blood concentrations differed
significantly between the patients treated with bevacizumab in first line and second line.
Median HSP27 expression in tumor cells in metastases was significantly reduced in patients
treated with DTIC in first line followed by bevacizumab when compared to the group of
patients treated with bevacizumab in first line. Most responders were found in the latter group
[14]. The reason why HSP27 expression was significantly reduced in patients treated with
DTIC in first line is not clear. Experimental studies have shown that exposure to both single
Expression of HSP27 in MelanomaMetastases Is Associated with Response to Bevacizumab
PLOSONE | DOI:10.1371/journal.pone.0155242 May 11, 2016 10 / 15
and repeated doses of DTIC could select for a more aggressive melanoma phenotype through
induction of VEGF and interleukin 8 by mechanisms other than HSP27 [49]. Thus, pretreat-
ment with DTIC in first line might have selected a more complex angiogenic phenotype, more
resistant to the specific inhibition of VEGF-A with bevacizumab.
Contrary, serum HSP27 was nine fold higher in patients treated with DTIC in first line fol-
lowed by bevacizumab. Although, the mechanism of HSP27 secretion is not yet completely
understood, release from necrotic cells after exposure to chemotherapy could contribute to
increased extracellular levels of HSP27 [50]. Similarly, to sHSP27, the concentrations of
pVEGF and s-bFGF were significantly higher in patients treated with DTIC in first line. This is
again pointing to the inverse relation between local and systemic levels of angiogenic factors,
and suggests that the increased systemic levels of these factors might have other sources than
the tumor cells [13].
There are limitations to the present study. One is the low number of patients included, with
a relative lack of statistical power. Another problem is the limited amount of tissue available
for analysis especially from some metastatic lesions. It is well known that tumor angiogenesis is
not evenly distributed and tends to occur in hot-spot areas. The sampling bias might therefore
reduce sensitivity and might have impact on the angiogenesis quantification by markers like
MVD and pMVD, as well as on the representativeness of intratumoral protein expression,
especially regarding small samples from metastatic lesions. However, metastatic melanoma tis-
sue was sampled in accordance with contemporary practice. It remains to be investigated if
such tissue samples are sufficiently robust for predictive purposes. On the other hand, since no
chemotherapy was given concomitantly, the findings are based on the effects of a single drug.
Another advantage is the availability of matched primary tumors and metastases as well as
serum and plasma samples. In addition, histologic features of the primary tumors as well as
clinical features and follow-up data, including response information, were available. Neverthe-
less, because of the low number of patients, limited amount of tissue, in some cases of core nee-
dle biopsies, as well as the lack of a randomized control group, the results must be interpreted
carefully.
In conclusion, our data indicate that strong expression of HSP27 protein in melanoma
metastases predicts overall response to bevacizumab monotherapy in patients with metastatic
melanoma. In contrast, multiple other angiogenesis markers, examined in tissues and blood
samples, showed no relationship with treatment response. Further randomized studies are nec-
essary to validate our findings.
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a: Staining index (SI); b: Standard error of mean (SEM) 
* p=0.097 (OR), p=0.046 (CB); Mann-Whitney U Test.  
 
S2 Table. Descriptive data for HSP27 expression in  







Mean SIa +/- SEMb 6.2 +/- 0.5 4.1 +/- 0.5 
Median SI* 6 3 
Minimum SI 3 2 
Maximum SI 9 9 
Number of patients 21 14 
a: Staining index (SI); b: Standard error of mean (SEM) 
* p=0.008; Mann-Whitney U Test 
 
S3 Table. Descriptive data for VEGF-A expression in primary tumors 
VEGF-A expression 
in primary tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean SIa +/- SEMb 5.2 +/- 1.0 5.1 +/- 0.5 5.6 +/- 0.6 4.8 +/- 0.6 
Median SI* 5 5 6 4 
Minimum SI 3 0 3 0 
Maximum SI 9 9 9 9 
Number of patients 6 26 11 21 
a: Staining index (SI); b: Standard error of mean (SEM) 




in primary tumors 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean SIa +/- SEMb 6.5 +/- 0.5 5 +/- 0.3 6.3 +/- 0.5 4.8 +/- 0.3 
Median SI* 6 6 6 6 
Minimum SI 6 2 3 2 
Maximum SI 9 9 9 6 
Number of patients 6 26 11 21 
S4 Table. Descriptive data for VEGF-A expression in metastases according to line of 
treatment 






Mean SIa +/- SEMb 5.4 +/- 0.5 3.2 +/- 0.7 
Median SI* 6 3 
Minimum SI 2 0 
Maximum SI 9 9 
Number of patients 21 14 
a: Staining index (SI); b: Standard error of mean (SEM) 
* p=0.016; Mann-Whitney U Test. 
 
S5 Table. Descriptive data for microvessel density (MVD) in primary tumors 
MVD in primary 
tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean MVD +/- SEMa 89.2 +/- 10.3 90.1 +/- 8.4 101.7 +/- 8.5 83.8 +/- 9.6 
Median MVD* 94.9 88.7 102.8 83.3 
Minimum MVD 53.2 23.1 53.2 23.1 
Maximum MVD 120.6 244.7 143.6 244.7 
Number of patients 6 26 11 21 
a: Standard error of mean (SEM); * p=0.62 (OR), p=0.042 (CB); Mann-Whitney U Test.  
 
S6 Table. Descriptive data for microvessel density (MVD) in metastases 
MVD in metastases Overall response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean MVD +/- SEMa 104.6 +/- 18.2 107.1 +/- 10.4 93.4 +/-14.7 112.4 +/- 11.2 
Median MVD* 97.5 108.2 86.0 115.3 
Minimum MVD 60.3 24.8 28.4 24.8 
Maximum MVD 154.3 212.8 154.3 212.8 
Number of patients 6 27 10 23 








S7 Table. Descriptive data for proliferating microvessel density (pMVD) in primary tumors 
pMVD in primary 
tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean pMVD +/- 
SEMa 5.0 +/- 2.0 6.0 +/- 1.4 5.2 +/-1.4 6.2 +/- 1.6 
Median pMVD* 4.4 3.5 3.6 3.6 
Minimum pMVD 0 0 0 0 
Maximum pMVD 14.2 30.1 14.2 30.1 
Number of patients 6 26 11 21 
a: Standard error of mean (SEM); * p=0.98 (OR), p=0.85 (CB); Mann-Whitney U Test.  
 
S8 Table. Descriptive data for proliferating microvessel density (pMVD) in metastases 
pMVD in metastases Overall response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean pMVD +/- 
SEMa 15.7 +/- 5.0 8.6 +/- 1.5 9.8 +/- 3.8 9.9 +/- 1.6 
Median pMVD* 11.53 7.1 5.3 8.9 
Minimum pMVD 5.3 0 0 0 
Maximum pMVD 35.5 31.9 35.5 31.9 
Number of patients 6 27 10 23 
a: Standard error of mean (SEM); * p=0.16 (OR), p=0.48 (CB); Mann-Whitney U Test.  
 
S9 Table. Descriptive data for vascular proliferation index (VPI) in primary tumors 
VPI in primary 
tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean VPI +/- SEMa 5.7 +/- 1.9 6.2 +/- 1.2 5.3 +/- 1.4 6.5 +/- 1.4 
Median VPI* 4.6 5.1 4.1 5.3 
Minimum VPI 0 0 0 0 
Maximum VPI 13.6 21.6 13.6 21.6 
Number of patients 6 26 11 21 
a: Standard error of mean (SEM); * p=0.98 (OR), p=0.82 (CB); Mann-Whitney U Test.  
 
S10 Table. Descriptive data for vascular proliferation index (VPI) in metastases 
VPI in metastases Overall response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean VPI +/- SEMa 15.5 +/- 3.8 9.2 +/- 1.8 10.1 +/- 3.2 10.5 +/- 2.0 
Median VPI* 15.4 7.6 7.8 7.8 
Minimum VPI 3.5 0 0 0 
Maximum VPI 29.0 46.2 29.0 46.2 
Number of patients 6 27 10 23 
a: Standard error of mean (SEM); * p=0.11 (OR), p=0.83 (CB); Mann-Whitney U Test.  
S11 Table. Concentrations of HSP27, VEGF-A and bFGF in blood samples according to overall response 
a: Standard error of mean (SEM); p=0.49 (HSP27), p=0.28 (VEGFA, plasma), p=0.72 (VEGF-A, serum), p=0.89 (bFGF); *Mann-Whitney U test.  
 
 
S12 Table. Concentrations of HSP27, VEGF-A and bFGF in blood samples according to line of treatment 
a: Standard error of mean (SEM); p<0.0005 (HSP27), p=0.017 (VEGFA, plasma), p=0.072 (VEGF-A, serum), p=0.002 (bFGF);  



















Overall response yes no yes no yes no yes no 
Mean 30.6 14.1 72.2 114.1 342.0 391.3 7.1 7.1 
SEMa 23.9 3.0 56.7 29.5 121.9 66.4 2.6 0.9 
Median* 4.8 7.4 14.0 74.0 255.5 381.0 7.2 8.2 
Minimum 0.9 1.1 0 0 66.0 18.0 0 0 
Maximum 149.0 49.2 353.0 615.0 901.0 1110.0 15.4 11.8 
Number of 




















st line 2nd line 1st line 2nd line 1st line 2nd line 1st line 2nd line 
Mean 7.1 29.8 53.3 169.6 267.1 511.9 4.6 10.0 
SEMa 3.1 10.5 18.3 48.5 49.2 100.3 1.2 0.7 
Median* 2.5 22.4 20 118.0 189.0 415.0 6.7 9.5 
Minimum 0.9 6.0 0 0 18.0 113.0 0 7.3 
Maximum 49.2 149.0 214 615.0 547.0 1110.0 10.7 15.4 
Number of 
samples 15 13 16 13 15 13 15 13 

